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1INTRODUCTION
Caesarean section was introduced in clinical practice as a
lifesaving procedure both for the mother and the baby. Caesarean
section rates have increased to as high as 25 – 30% in many areas of the
world1.
Delivery by caesarean section causes more complications than
normal vaginal delivery. One of the most common complications is
primary and secondary postpartum hemorrhage2. Obstetric haemorrhage
can be life threatening. Major haemorrhage continues to be one of the
most common causes(25%) of direct maternal death3. Confidential
enquiry in to maternal death 2000-2002 in UK reveals that 17% deaths
were due to haemorrhage. In order to reduce mortality and morbidity
due to obstetric haemorrhage we need to reduce the amount of bleeding
at caesarean section1.
Blood loss in caesarean section frequently leads to transfusion of
allogenic blood products. (Alexander et al 2009) reported that 2.3%
were given blood transfusions for hypovolemia in caesarean section and
this is related to increased maternal morbidity and mortality 4. Each unit
of transfusion of blood or blood products exposes the patient potentially
2to the risk of transfusion related adverse effects such as febrile non
haemolytic reactions, blood borne infections and errors in transfusion.
Blood is a scare resource, even when it is available the safety of
blood transfusion and shortages of blood products, and rising costs of
blood bank operations have generated interest in reduction of blood
transfusion during and after surgery. A popular approach is to reduce
perioperative blood loss through the prophylactic use of anti fibrinolytic
agents. Aprotinin, tranexamic acid and epsilon amino caproic acid are
the three anti fibrinolytics5.
Tranexamic acid is a synthetic derivative of lysine. The anti
fibrinolytic activity of tranexamic acid is a result of interference with
plasminogen binding to fibrin. It reversibly blocks the lysine binding
sites on plasminogen molecules6. Intravenous administration of
tranexamic acid had been used for many years for reducing blood loss
in surgeries like cardio pulmonary bypass, orthoptic liver
transplantation,transurethral prostatic surgery, total hip or knee
arthroplasty, urinary tract surgery. Tranexamic acid has been shown to
be very useful in decreasing blood loss and the incidence of blood
transfusion in these surgeries.
3The changes in the fibrinolytic components during and
immediately after placental delivery are consistent with increased
fibrinolysis and the plasma fibrinogen level decreases during 3rd stage of
labour and afterplacental delivery19.   Hence anti fibrinolytics will be
useful and effective in reducing blood loss by interfering with the
fibrinolytic mechanism. In this study the efficacy and safety of
tranexamic acid in reducing blood loss during and after LSCS was
investigated.
4AIM OF THE STUDY
1. To evaluate the efficacy and safety of preoperative intravenous
tranexamic acid in reducing blood loss during and after caesarean
section.
2. To compare it with the amount of blood loss in patients who did not
receive tranexamic acid preoperatively.
5REVIEW OF LITERATURE
Caesarean delivery is defined as delivery of the baby through an
incision in the abdominal wall and uterine wall.
Caesarean section rates have increased over the last 20 years
around the world including in India. Collaborative study done by Indian
council of Medical research showed that the overall caesarean section
increased from 21.8% in 1993-1994 to 25.4% in 1998-1999 (Kambo et
al  2000)1.
Caesarean section rate was almost 40 to 45% in the private sector
(Srividhya et al and SathyaSekaranet al2003)8.  A similar study by Pai et
al 1999showed almost one in two women had a caesarean section in
affluent societies of India9.
The increase in average maternal age, and increased use of
electronic foetal monitoring and widespread use of labour induction, and
reduced incidence of instrumental deliveries, increased prevalence of
obesity, reduced incidence of vaginal birth after caesarean (Hamilton et
at 2009) and increasing rate of elective caesarean for medically
indicated preterm birth and patient request(Ananth et al 2005,Nygaard
etal2003) are some of the reasons for increasing caesarean rate.
6Although caesarean sections are lifesaving procedures that are common
in obstetric practice it has its own complication.
Haemorrhage is the most common complication following
caesarean section, the excess blood loss in caesarean section is due to
bleeding from the placental site and also from the uterine incision. The
incidence of post partum haemorrhage was doubled   in caesarean
section(6to8%) when compared  (3.9%) to vaginal deliveries10,11.(combs
et al 1991), (Naef et al 1994).
The maternal mortality and morbidity increased two to nine fold
with caesarean delivery compared with vaginal delivery12 (Villar et al
2007).  Haemorrhage is one of the principal sources of maternal
mortality and morbidity in caesarean section13(Burrows et al 2004).
Blood loss during caesarean section
Blood loss during normal vaginal delivery may be up to 500 ml.
The average blood loss  during  caesarean  section  is1000  ml and
1000 to 1500 ml in caesarean hysterectomy,  and  in  emergency
caesarean hysterectomy  is  3000ml14Pritchard et al 1962).
However blood loss of even 200 ml can be life threatening in
woman with severe anaemia (Kongnuy et al).
7Physiological adaptations during normal pregnancy:
There is about 40 – 45% increase in plasma volume  from 2600ml
to3850ml and 25% increase in red blood cell volume  from1400ml to
1640ml after 32 – 34 weeks of pregnancy15 (Pritchard et al 1965). This
protective haemodilution initiates fall in haemoglobin, haematocrit, and
red cell mass but maintains the mean corpuscular haemoglobin
concentration. Blood volume rises by 37% from 4000ml to 5500ml
providing not only adequate perfusion and also compensatoryre serve so
that a healthy woman can tolerate acute blood loss upto 1000ml.
The haemostatic mechanism in normal pregnancy is characterized
by increased level of procoagulant factors like factor VII, VIII, X and
fibrinogen and marked decrease in fibrinolytic activity. Parturition
makes a serious threat to vascular compartment, but the contractility  of
the myometrium  the ” living ligatures”   of  the uterus is the mechanism
which mainly controls the blood loss during labour and caesarean
section.  Though the myometrial contraction is the prime factor which
controls the blood loss during delivery followed by the formation of clot
and deposition of fibrin that occur rapidly are essential in maintaining
haemostasis(SleepJ et al1993).
8Blood coagulation and fibrinolytic system
Coagulation cascade constitutes the third component of the
haemostatic process, the first and second is being the endothelial
response to tissue injury, and platelet aggregation and deposition
respectively16 (Hoffman et al 2001).
The cascade consists of series of enzymatic reactions leading to
cleavage of prothrombin to thrombin. Thrombin converts soluble
plasma protein fibrinogen into fibrin monomer which then polymerises
into insoluble fibrin. Factor XIII an enzyme is also activated by
thrombin which catalyzes the formation of covalent bonds between
fibrin molecules and form a clot that is resistant to dissolution17.
(Anderson et al 1965).
The fibrinolytic system gets activated by deposition of fibrin and
it maintains the patency in damaged blood vessels. Fibrinolysis is
mediated by plasmin which is derived from break down of inactive
circulating precursor plasminogen.
Plasminogen binds to lysine residues on the surface of fibrin and
is converted to plasmin by tissue plasminogen activator (t-PA) which is
released from the endothelial cells. Plasmin interferes with fibrin
polymerization and a break down it’s into fibrin degradation products.
9Excessive fibrinolysis is prevented by naturally occurring protease
inhibitor called alpha 2anti plasmin.
The balance between the coagulation and fibrinolytic mechanism
keeps the vascular compartment intact and patent.  Fibrinolytic activity
is known to be decreased in late pregnancy and labour and return to
normal in early pureperium18(Biezinski JJ et al 1958).
Definition of PPH:
There is no single satisfactory definition proposed
? WHO  defines  PPH  as  blood  loss  >  500  ml  in  the  first  24  hours
after delivery and more than 1000 ml of blood is lost in severe
PPH (Mousa and Al firevic et al 2007)
? ACOG (2006)– defines as blood loss which  decreases
haematocrit by 10% or needs transfusion
? Clinically, amount of blood loss results in haemodynamic
instability. Because of wide range of definition applied to
maternal haemorrhage and their imitations, it is important to
combine the clinical presentation and objective data
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Incidence of PPH
 2 to 11% when blood loss is estimated visually (Brent et al.,
1967) and 20% when quantitative methods are used (Newton et al.,
1969)
Classification of PPH
Primary PPH: PPH which occurs within first 24 hours
postpartum.
Secondary PPH: PPH occurs between 24hrs postpartum and 6
weeks after delivery   (Kominiarek et al and Kilpatrick et al 2007)
Potential causes of increased blood loss during caesarean section
Factors are divided into four major groups:
? Tone
? Tissue
? Trauma
? Thrombin
Tone: 80 to 90% cause for PPH
The following are the predisposing factors.
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? Over distended uterus – Polyhydramnios, multiple pregnancy,
Marosomia
? Multi parity
? Precipitate labour
? Prolonged labour
? Prolonged rupture of membranes
? Chorioamnionitis
? Fibroid complicating pregnancy
? Placenta Previa
? Abruptio Placenta
? Uterine anomalies
? Prolonged Induction of labour
? Inadverent  use of  oxytocics
? Drugs: halogenated  anaesthetics
  Magnesium Sulfate
  Nifidipine
  Beta agonists
Trauma: 20% second most common cause
Factors responsible for increased blood loss in caesarean section are,
? Pfannensteil  incision
? Classical caesarean section
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? Malposition of foetal head
? Transverse lie
? Obstructed labour with deeply engaged head
? Large baby
? Poor obstetrician skill
Tissue: 10%
? Retained cotelydon, succenturiate lobe
? Retained products of conception
? Placental abnormalities like placenta accreta, increta, percreta
? Retained blood clots
Thromboticdefect: 5%
? Preexisting coagulapathies like hemophibia A, Von willebrand’s
disease, ITP
? Acquired coagulation defects causing DIC like
HELLP syndrome
Abruptio placenta
Intra uterine foetal death
Septicemia
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However   half  of the  woman  who  had  atonic  PPH   after a
primary caesarean section the risk factorswas not identified (Rouse et al
2006).
Consequences of uncontrolled Haemorrhage include:
? Hypovolemic shock leads to organ failure including renal failure
myocardial infarction, stroke.
? Severe intra partum or postpartum haemorrhage during and after
caesarean section may leadsto rare complication hypoperfusion
of pituitary and necrosiscalled Sheehan syndrome. It is
characterized by failure of lactation, amenorrhoea, breast atrophy,
adrenal cortical insufficiency.
? Massive blood loss may leads to irreversible shock and death.
Complications of Fluid Resuscitation:
? Fluid overload following acute haemorrhage in caesarean section
may leads to pulmonary oedema and oedema in the extremities.
The former should be suspected in case of massive fluid and (or)
blood product resuscitation.
? Dilutional coagulopathy may occur in large volume crystalloid
and packed red cell transfusion. Since they neither contain
coagulation factors nor platelets.
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Complications of blood transfusion:
Allergic (or) Non haemolytic febrile reactions are the commonest
with an incidence of 1 in 330 populations
Anaphylactic reactions occur in 1 in 20,000 to 47,000 blood
transfusions
Transfusion – related acute lung injury(TRALI):
It occurs in 1 in 5000 transfusions. It develops within 6 hours of
transfusion23 (Silliman et al 2003). Sometimes delayed type TRALI
occurs in 6 to 72 hours following transfusion24 (Marick & Corwin et al
2008).
It is due to interaction of recipients with pre-existing donar
leucocyte antibodies caused by transfusion of plasma containing blood
products.(kapko 2000 et al). This is a life threatening complication
characterized by hypoxia, dyspnoea, and non cardiogenic pulmonary
edema.
Acute Immune haemolytic reaction:
Transfusion of an incompatible blood component may result in
haemolysis. Patient may present with fever, tachycardia, hypotension,
chestpain, flushing. An anxiety and death may results if the transfusion
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is not stopped. It is a medical emergency, and the management of the
reaction precedes investigation into its cause.
Delayed Reaction:
This subset of reaction results from incompatibility with minor
blood group antigens other than ABO blood group. This may manifest
between 7 and 21 days. Patient may be asymptomatic with reduced
haematocrit, mild jaundice, and positive for direct anti globulin test.
Transfusion related infections:
Donor blood is routinely screened for hepatitis B, C, HIV &II,
Malaria andsyphilis. Despite screening the risk of transfusion still
occurs since the donor may have been in the window period without a
detectable immunologic response at the time of donation.
   Highest rate of transmission is with hepatitis B 1 in1,00,00025
(Jackson et al 2003).(Centers for Disease control and prevention 1995)
The risk of Transmission of HIV 1&2 is about 1 in 2 million cases. The
risk of Hepatitis C is about 1 in 2 million cases.(Stramer et
al2004).Lyme disease, Toxoplasmosis, chagas disease, cytomegalovirus,
babesiosis are other rare transfusion related infections.
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Metabolic complications:
Patient is at risk of metabolic complications like hypothermia,
hypocalcemia, and hyperkalemia.
Hypothemia: May  results  from  transfusion  of    un  warmed  blood
products results from this toxicity.
Hypocalcemia: This occurs with large volume of transfusion caused
by citrate an additive product that binds with serum calcium.
Hyperkalemia: Transfusion of older red blood cells increases the risk
of hyperkalemia. Administering tranexamic acid would reduce both
units of blood required and reduce the probability of acquiring infection
like HIV, HBV, and HCV through transfusion.
Risk associated with surgical intervention:
Intubation and anaesthesia related complications:  increased risk of
aspiration, failed intubation, and death from failed ventilation are more
common in pregnant woman compared with non pregnant woman.
Respiratory tract injury, myocardial infarction, arrhythmias, and allergic
reactions to anaesthetic medications are other rare complications.
Bleeding: continued bleeding from the genital tract or excessive
bleeding may result from a surgical complication.
17
Infection: prolonged surgery may results from wound infection,
pneumonia, and sepsis.
Deep vein thrombosis and pulmonary embolism: The  risk  is
increased due to pregnancyinduced hypercoagulable state, and
associated postoperative hypercoagulability and also relative immobility
in the post-operative period may predisposeto this complication.
BLOOD LOSS ASSESMENT
Accurate measurement of amount of blood lost after child birth
help us to quickly diagnose the life threatening haemorrhage. Caesarean
section is particularly associated with varying degrees of blood loss28
(Sulle et al 2005). The blood loss assessment has to be standardised in
order to assess the efficacy of the drug.
Different methods have been used to measure the blood loss
? Clinical methods:
a) By subjective characters
b) Visual assessment
? Direct  methods:
? Laboratory based measurement
? Others
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Clinical  Methods:
Estimation of blood loss by using subjective characters.
? Shock Index:
SI =  Heart rate
        Systolic BP
Normal range: 0.5 – 0.7
If increases to 0.9 – 1.1 with significant Haemorrhage.
Rule of 30:
? If systolic BP falls by 30mmHg
? Heart rate rises by 30bpm.
? Respiratory rate rises by 30 breaths per minute
? Haematocrit drops by 30%
? Urine output <30ml per hour.
If all the above parameters exist the patient must have lost30% of blood
volume.
Assessment based on severity of haemorrhage27:
(Gutierrez et al 2004) classifies into 4 classes:
Class I:
? Mild bleeding
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? Patients have lost <750 ml of blood or <15% of blood volume.
? No change in vital signs, postural hypotension, urinary output.
Class II:
? Moderate bleeding
? 15 to 30% of blood volume loss or 750 – 1500 ml blood loss
? Exhibit  baseline tachycardia, and anxiety
? Postural variation in pulse rate about 10-20bpm, increase of pulse
rate from supine to upright position
? More than 10mm Hg drop in diastolic blood pressure
Class III:
? 30-40% of blood volume loss (or) 1500-2000 ml of blood loss
will be present.
? Extreme  tachycardia,  heart rate 120 – 140   per minute
? Mental confusion will be present
? Blood pressure very much decreased
? Very much decreased urine output <15ml
Class IV:
? >40%  of blood volume lost or more than 2000 ml of blood will
be lost
20
? Patient will be in shock with feeble pulse and unrecordable blood
pressure and Oliguria (or) anuria
Visual estimation:
Most commonly practiced method, major advantage of this
method is a real time assessment and enables us to correlate findings,
but various studies showed significant differences between clinical
estimates and the actual measurement.
(Prasertcharoenusket al2000)    The incidence of PPH was
underestimated in the visual estimation28.
(Duthie et al 1991) Showed that there was significant
underestimation of blood   loss during caesarean section29
(Stafford et al)   The tendency to underestimate the blood loss
was greater with calculated loss of >1000ml.
P.Bore et al 2006
           10   x 10 cm    swab =60 ml
           30   x   30 cm   swab        = 140ml
           45   x   45 cm   swab       = 350 ml
           One kg of soaked swab  = 1000ml
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           50 cm floor spill        = 500 ml
           75   cm floor spill      = 1000 ml
           100   cm floor spill    = 1500 ml
Direct methods:
Oldest method of determining blood loss. Following methods are
mainly used to measure blood loss after normal vaginal delivery.
? Bed pan and standard measuring jar
? Rubberized blood mat
? Kelly’s pad
? Calibrated drape method.
Gravimetric method:
It is a direct method of estimating the blood loss which can be
used in caesarean section to estimate the blood loss.
? Patient weighing method
? Swab weighing method
Patient weighing method:
Measure the weight of the patient prior to and after surgery.
Allowance must be made for infusion, drain, and insensible water loss
and tissue removal.
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Swab weighing method:
By measuring swabs prior to and after surgery and blood
absorbed by the swabs would be the difference.
? 1 gm of weight gain  = 1 ml of blood loss.
(Bonica et el 1951), Harding et al 1984)
  The soaked pads should be weighed immediately after surgery in
order to avoid estimation errors due to evaporation. This will
minimize the inter observer variation orinconsistency in
measurement.
? This is the method which is practically possible and is followed in
our study.
? Swab weighing is considered a standard method for comparability
because it represents a practically real value which is neither
dependent on personal bias nor dependent on hypothetical
values30 (Ashraf aly et al2006).
? (Prasertcharoensuk 2000et al) Swab weighing is a gold standard
method against other methods in determination of blood loss
during caesarean section.28
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Laboratory based Measurements
Calorimetric method:
(Roe’ et al 1962, Thornton et al 1963 Rustod et al 1963)
The contaminated blood swabs are washed with known volume of
tap water and sufficient amount of ammonium hydroxide added as a
deformingagent to give a 1 in 1000 dilution. Blood collected in the
suction container has to be added to the water and the resultant solution
concentration has to be determined.
Blood loss in ml =Hb % of washing fluid & volume of washing fluid
                    Hb% of patientsblood x dilution factor of
                  patients Hb%
Alkalinhematin (or) acid hematin method:
It is a method based on when collected blood is mixed with
standardized solution which converts haemoglobin to acid haematin (or)
cyanomethemoglobin. This is turn can be measured by a
spectrophotometer or calorimeter.
Measurement of blood in the suction container:
Blood in the suction container can be measured. In accuracy due
to mixing of amniotic fluid can be reduced by having measuring
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cylinder in the suction line and by adding deforming agent to the
container.
Electrolyte  conductivity method:
(Rubricius et al and Leveen et al 1958) Using automated blood
loss meter based on electrolyte conductivity.
Radioactivity method:
(Murray and Dotts et al 1960)Preoperative Intravenous injection
of small and known amount of radioisotope should be followed by
measuring the radioactivity of blood soaked swabs collected during
surgery.
Blood volume Measurements:
? Dye method:
? The dye should neither catabolised nor rapidly removed from the
circulation
? Evans  blue dye can be used for measuring blood volume
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Radio Isotope Method:
(Mollison and veall et al., 1955)
Radio isotope like I 131 labelled albumin (or) Cr 51labled RBC can
be used before surgery and measuring the post operative radioactivity by
Geiger muller counter.
Measures to reduce blood loss in caesarean section:
The blood loss during Caesarean can be minimised by
?Good antenatal care.
?Proper preoperative preparation.
?Efficient intra operative measures
?Good post operative care
Good Antenatal care:
Ideally the women should have regular antenatal visits.
? Correction of antenatal anaemia
? Identification of risk factors like maternal foetal and placental
complications.
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Preoperative Preparation:
? Blood grouping and Rh typing
? Expecting blood loss in high risk cases, and reservation of
adequate blood products preoperatively.
? Correction of coagulation abnormality before surgery in cases of
Abruption placenta, IUFD and HELLP syndrome.
? Prophylactic use of antifibrinolytics before surgery.
? Regional anaesthesia is preferred one unless it is contraindicated.
Intra operative measures:
? Joel Cohen (Joel cohen 1977) described a transverse skin incision
is placed 3 cm below the line joining the anterior superior iliac
spine. The subcutaneous tissue and anterior rectus sheath are
divided by blunt finger dissection.
(Mathai and Hofmeyer 2007) at el, compared to pfannensteil
incision the Joelcohen incision is associated with less blood
loss33.
? Lower segment incision is preferred over classical caesarean
section34  (Berghella et al 2005)
? Blunt expansion of uterine incision with fingers.
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(Magann et al 2002, Sekhavat et al 2009), observed thatsharp
dissection of uterus associated with greater blood loss35.
? To push the deeply engaged head from below upward by an
assistant in obstructive labour.
? Patwarthan’s or modified patwarthan technique can be used for
delivering baby in obstructed labour.
? As soon as the head is the delivered 10 units of oxytocin should
be added to the drip and 10 unitsi.m. should be given. This is an
important step that enormously reduces the amount of blood loss.
? Placental cord blood   drainage may be used to reduce the blood
loss   in caesarean section36 (sharma.JB, et al1995).
? Though the blood loss was reduced by active management in the
third stage   but the adverse effects like nausea, vomiting are
high37(Prendiville et al ., 2002)
? Delayed cord clamping for 60 seconds has the benefit of reducing
blood loss and increasing iron stores and decreasing anaemia.
This delay does not adversely affect the foeto maternal outcome38
(Lasely et al 2005).
? Spontaneous delivery of the placenta associated with less blood
loss compared to manual removal in caesarean section39.
[wilkinson et al, Enkin et al 2000] (Farcesa et al, Raziaetal 2008)
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Post operative measures:
? Strict vigil is needed in high risk cases.
? Oxytocics can be continued post operatively in high risk cases
expecting post partum haemorrhage.
Management of PPH  during caesarean section
[RCOG green top guide lines 2009]
? Call for help
? Asses the general condition of the patient
? Vital parameter should be monitored
? Oxygen 4-6 litres through face mask should be given
? Establish additional  intravenous access with a large bore cannula
? Arrange for blood transfusion
? In the mean time, crystalloids and colloids can be given
Isotonic crystalloids are the preferred solutions over colloids
because of the quick distribution into the vascular system and are
cheap and do not associated with adverse reactions like
anaphylaxis as with colloid.
? Transfuse blood as soon as possible blood should be warmed
prior to transfusion.
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? If bleeding time, clotting time likely to be prolonged replace it
with coagulation factors and platelets.
Medical Management:
Uterotonic agents:
(i) oxytocin
          10 units i.m. followed by 20-40 units per litre of RL/NS infusion.
? Oxytocin stimulates the upper segment of the myometrium
causing rhythmic contractions which constrict blood vessels there
by it reduces blood flow through the uterus40. (Blanks AM et al
2003).
? Half life is 3 minutes, only parenteral preparations are available.
? Stimulates uterine contractions and has vasopressive and ant
diuretic effects.
? Rapid Intravenous boles dose cause hypotension41 (Secher et al
1978).
? Large volume of doses can cause water intoxication42. (Whalley
and pritchared et al 1963)
(ii) Methyl ergometrine:
? 0.25 mg or IV repeat every 5 to 15 minutes as needed
Max: 5 doses
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? Ergot alkaloids cause generalized smooth muscle contraction in
which the upper and lower segments contract tonically43 (De
costa et al 2002).
? It can be given intravenously, intra muscularly or orally.
? It raises blood pressure hence contraindicated in preeclampsia
and cardiac diseases. Other adverse effects are nausea and
vomiting.
(iii) Syntometrine:
Combined oxytoxin (5 units) and ergonavine (0.5 mg)
oxytoxin is preferred over syntometrine in reducing blood loss
during third stage of labour44. (choy et al 2002)
Prostaglandin:
? 15 methyl prostaglandin alpha (carboprost)
? It enhances uterine contractility and also causes vasoconstriction.
? It can be administered intra myometrially (or) intra muscularly in
a dose of 0.25 mg
? Dose  can  be  repeated  every  15  minutes  for  a  maximum  of  8
doses.
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? It controls haemorrhage in 87% of the patients45 ((Lamont RF et
al 2001).
? Side effects:
Nausea, vomiting, diarrhoea, hypertension,headache, pyrexia
Absolute contra indication:  bronchial asthma, hypersensitivity
Misoprostol
? PGE1  analogue
? It increases uterine tone there by it reduces bleeding
? Can be administered orally, rectally, vaginally, sublingually.
? FIGO recommends 1000 microgram rectally for post-partum
haemorrhage.
? Side effects: shivering, pyrexia and diarrhoea
Recombinant factor VII a:
? Enzyme of  serine protease class
     It initiates coagulation in conjunction with tissue factor.(Ahonen
    et al 2007).
? It form a complex with tissue factor at the site of vascular injury
independent of the presence of factor VIII and IX.
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? Administration in high doses increases its level above the
physiological level and promotes thrombin generation.
? (Franchini et al 2007)
Factor VII A, will not work without fibrinogen and suboptimal
results with thrombocytopenia (<20 X109 /l)
Antifibrinolytics
Tranexamic acid:
The fibrinolytic system gets activated during 3rd stage of labour.
During placental delivery fibrinogen and fibrin are rapidly degraded
whereas plasminogen activators and fibrin degradation products
increases due to activation of fibrinolytic system. This activation can
last up to 6 to 10 hours of postpartum causing  more bleeding.
Tranexamic acid potentiates clotting system by means of inhibition of
fibrinolytic mechanism70 (okamoto et al 1962).The anti fibrinolytic
effect of tranexamic acid could make the drug as effective and safe
alternative (or) adjunct to other regimens which are currently practiced
during caesarean section. Tranexamic acid also reduces blood loss from
the upper placental site and conditions like placenta previa and genital
tract injury. The drug may be particularly useful in preventing bleeding
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due to factors other than uterine atony where  uterotonics will not he
effective21 (Mousa et al 2007).
Tranexamic acid is an inhibitor of fibrinolysis that blocks the
lysine binding sites of plasminogen and prevents its binding with
fibrin4(Astedt 1987, Longstaff 1994).
It has been used in many years to reduce blood loss during
haemorrhage, and is reported to reduce intra operative and post-
operative blood loss47, 48,49,51,52.
Boylan et al 1999
Karski et al 1995
Katsaros et al 1996
Reid et al 1997
Vacharaskar et al  2002.
Adverse effects are very minimal; occur in 10% of patients
usually limited to gastro intestinal tract such as nausea, vomiting,
diarrhoea.
Rare complications are hypotension, thrombosis, blurring of
vision, renal cortical necrosis.
Retinal artery obstruction46 (Asted et al 1987)
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However(Bekassy et al 1990) tranexamic acid   was not
associated with any adverse effects.
? Tranexamic acid reduces blood loss from placental delivery to 2
hours post-partum without any side effects or complications54(Gai
M Y et al 2004).
? Tranexamic acid significantly reduces blood loss from end of
caesarean section to 2 hrs postpartum without any
complication55(sekhavat L et al 2009).
? Tranexamic acid reduces blood loss during caesarean section and
bleeding more than 1000ml. The need for additional uterotonics is
also reduced56. [Gungoruduk k et al 2001]
? Tranexamic acid can be safely and effectively used in caesarean
section without any complication like thrombosis57.  (  shahid  A.
Khan A. etal 2013)
? The use of  tranexamic acid in abruptio placenta reduces  blood
loss and  perinatal morality rate without any haemorrhagic
diathesis or thrombosis (Lars et al, Birger Astedt et al 2011)
? Tranexamic acid 10 mg/kg intravenously prior to skin incision
with women undergoing LSCS reduces blood loss46(Astedt 1987).
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? Use of tranexamic acid potentially prevented some form of PPH
in those with high risk factors for PPH21. (Mousa 2007)
(Cochrane review on treatment of PPH)
? Tranexamic acid reduces 58% of menstrual blood loss in
dysfunctional uterine bleeding due to its effect on the fibrinolytic
enzymes in the endometrial cavity59(Gleeson et al, Fiona Buggy
et al 1994].
? Tranexamic acid decreases bleeding, maternal morbidity in on-
going PPH (Anne sophie et al,Ducloy et al 2011)
? Prophylactic treatment with tranexamic acid reduces post-
operative bleeding after conization60.(GoranRybo et al, Hans et al
1972)
? Tranexamic acid is cost effective drug and its prophylatic use
reduces blood loss and money in total hipreplacement (Johansson
2005).
? Antifibrinolytics tranexamic acid and aprotinin  use  reduces
blood transfusion requirements during Liver transplantation
without any increased incidence of thromboemboliceffects61.(I.Q.
Molenaar et al, warnaar 2007)
? The  use  of  high  dose tranexamic acid loading dose  of 4 gm
over 1 hour followed  by   1gm  per  hour  over 6 hours in post-
36
partum haemorrhage reduces the amount of blood loss and
maternal morbidity with mild and transient  side effects62.(Ducloy
et al2011).
      CRASH-2  TRIAL
Clinical randomization of an antifibrinolytic in significant
Haemorrhage (CRASH -2) showed tranexamic acid reduces the
risk of death, and transfusion requirement and bleeding in trauma
patients and also it is a cost effective drug63.
? Tranexamic acid significantly reduces the amount of bleeding
during and after caesarean section64 (Patilpurvi 2007).
? Tranexamic acid reduces blood loss and the need for blood
transfusions in cardiac surgery, liver transplantation, and
orthopaedic surgery65 ( Dunn 1999) Cochrane review (2009).
? Intra venous administration of Tranexamic acid 10 mg /kg prior to
sternotomy reduces post-operative drainage and transfusion
requirements in coronary artery bypass surgery66(MM.Maddali et
al2007).
? Tranexamic acid reduces the need for allogenic red blood cell
trans fusion in patients undergoing hip replacement  (Erik
Learney et al, Alain Roy et al).
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? WOMAN trial (world maternal anti fibrinolytic trial)67 :  Use  of
Tranexamic acid for the treatment of postpartum haemorrhage.
An international randomised double blind placebo controlled trial.
On-going trial results are expected in 2015 February.
The trial includes 15000 women with clinical diagnosis of post
partum haemorrhage.
All women with clinically diagnosed post partum haemorrhage
following caesarean or vaginal delivery are included.
The fundamental eligibility criterion is the responsible clinician
uncertainity as to whether or not to use an anti fibrinolytic agent
in a particular woman with post partum haemorrhage.
After randomization.1 gm of tranexamic acid by intravenous
injection or placebo (0.9 sodium chloride) given as seen as
possible.
If bleeding continues after 30 minutes  or further episode of
bleeding within 24 hrs 2nd dose of drug should be given
TAMPONADE TECHNIQUES
? (Condus GS, Arul Kumaran et al) Sengstaken black more tube
can be used both therapeutic and diagnostic purpose.
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? (Maier et al 1993. Hsu et al 2003) Uterine tamponade is very
useful in controlling bleeding due to uterine atony and placental
site bleeding.
Surgical Techniques:    Conservative methods
? Placental bed suturing (Arul Kumaran et al 1999)
? Devascularize the post caesarean section uterus with bilateral
mass ligation of ascending branches of uterine arteries and
veins.(O’Leary et al 1995)
? Stepwise devascularisation (Abdrabbo et al  1994 )
? Pair of vertical brace sutures compress the anterior and posterior
wall of uterus achieving haemostasis.(B Lynch et al 1997)
? Modified B Lynch (Hayman et al 2002)
Pair of vertical braces sutures without opening the uterine cavity
in addition horizontal cervicoisthumic opposition suture after
reflecting the bladder
? Cho’s multiple squaring sutures (cho et al 2000)
? Uterine artery embolisation. (Raveena et al 1991)
It is done in a hemodynamically stable patient with persistent
bleeding.
Success rate 73-100% (Chalers et al 2008)
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Hysterectomy
It is done when all the available measures have been tried and
failed.
TRANEXAMIC ACID
CHEMICAL STRUCTURE:      H
  o     o
    H N
                                                                  H
Chemical Name : trans -4- (aminomethyl) cyclohexane carboxylic acid.
Molecular Formula : C8 H15NO2
Molecular Weight : 157.21
Melting point : 300?c
PH of aqueous solution             :  6.5 to 8.0
Storage at 25?C
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Classification  : It is an antifibrinolytic drug
It is a synthetic derivative of amino acid lysine and exerts its
antifibrinolytic effect through reversible blockade of lysine binding
residues on plasminogen molecules.
Pharmaco dynamics:
The dug has two isomeric forms the antifibrinolytic potency
resides in the trans isomeric form79 (okamoto et al1964). The
antifibrinolyic effect is mainly results from the formation of reversible
complex of the drug with plasminogen.  The lysine binding sites of
human plasminogen are important sites of interaction for the synthetic
antifibrinolytic derivatives, fibrin and alpha -2- antiplasmin69(thorsen et
al 1975).
Tranexamic acid binds with lysine residues of plasminogen
molecules and competitively inhibits activation of plasminogen there by
reducing conversion of plasminogen to plasmin.
At much higher concentration itnoncompetitively inhibits
plasmin. Comparison studies between tranexamic acid and epsilon
amino caproic acid showed tranexamic acid is about 10 times more
potent than the later.
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? Tranexamicacid bind more strongly than amino caproic acid to
both strong and weak receptor sites of plasminogen molecules in
a ratio corresponding to the difference in potency of these
compounds.
? Tranexamic acid in a concentration of 1 mg /ml does not
aggregates platelets invitro
? Tranexamic acid has no influence on the platelet count and the
coagulation time, (or) various coagulation factors in the whole
blood (or) citrated blood innormal subjects up to 10mg/ml
concentration in blood. On the other hand when the concentration
is> 10mg/ml in blood prolongs the thrombin time71(Widlund L
Stromberg S et al 1970).
Pharmacokinetics:
30-50 % of the orally administered drug is absorbed and its
bioavailability is not affected by food intake72 (Tovi et al 1972).It does
not binds with serum albumin.
After intravenous administration of 1gm of drug the plasma
concentration time curve shows tri exponential delay with a half  life of
about 2 hours for the terminal elimination phase.
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Distribution:
Volume of distribution of drug is about 9 to 12 litres. The peak
plasma level is 8mg/l after 1 gm oral dose and 15 mg/l after 2gm oral
dose after 3hours of administration73(Kullander et al1970).
Anti fibrinolytic concentration of tranexamic acid remains in
different tissue for about 17 hours and about 7-8 hours in the serum.
Metabolism
Majority of the administered drug is remain unchanged only a
small fraction of drug is metabolised.
About 1% of dicarboxylic acid and 0.5% acetylated compounds
are excreted after oral administration.
Excretion:
Renal excretion is the main route of elimination via glomerular
filtration. 95% of the dose is remains unchanged and excreted through
urine. After intravenous administration 90% of the drug is execreted
through urine with 24 hours cumulative urinary execretion is about 39%
is 24Hrs74(Walzman et al 1971).
The drug crosses the placenta. After I.V. Injection of 10mg/kg to
a pregnant woman the cord blood concentration is about 30 mg/l.
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The drug rapidly diffuses in to joint spaces and synovial fluid.
The concentration is almost equal to that of serum the half-life is 3
hours in joint fluid(Bonnar J et al 1971).
In the breast milk the concentration is about one hundredth of
peak serum concentration.
The drug crosses blood brain barrier, CSF concentration is about
one tenth of plasma.
Very small amount of drug is detected in semen where it inhibits
fibrinolytic activity but it does not influence sperm motility.
Uses:
The drug can be used in all types of bleeding especially
coagulopathic bleeding. The drug can be used prophylactically before
surgery where excess bleeding is expected.
? Caesarean section
? Post partum Haemorrhage
? Bleeding due to coagulation defect
? Cardiac surgery like cardio pulmonary bypass
? Trans urethral resection of prostate
? Liver transplantation  surgery
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? Orthopaedic surgeries like  spine surgery, total knee or hip
replacement
? Dental extraction  is haemophilia  patients
? Non hormonal agent in menorrhagia and dysfunctional uterine
bleeding.
Adverse effects:
? G1 disturbance about 10% include nausea, vomiting, diarrhoea.
? Sudden rapid intravenous infusion may cause giddiness and
hypotension
? Defective colour vision76,77(Ekvaran et al 1983),(Thelil PL et al).
? Drug allergy
? Thrombo embolism
? Un usual tiredness  and weakness
? Unusual menstrual discomfort
? Watery eyes78(Robble et al 1995,Lindoff et al).
Contra indications:
? In  patients with past H/o thrombo embolism
? In patients with subarachnoid haemorrhage the drug may
causecerebral edema and cerebral infarction.
? Patents with defective colour vision
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? Renal failure, liver failure, cardiac diseases
Drug interaction:
? Chloropromazine increases cerebral vasospasm when it is
combined with tranexamic acid so it should not be combined.
? Concurrent administration of heparin does not interfere with the
anti fibrinolytic activity of tranexamicacid75 (Van riper et al
1993).
Should be cautiously used in
? H/o allergy
? H/o Renal / Liver disorder
? Pregnancy – category ‘B’ drug can be safely used in lactating
mother.1% maternal serum level will be reached in breast milk.
Preparation and dosage:
? Oral -500mg tablets
? Intravenous- available as 5 ml 10 ml ampules 1 ml contain 500mg
Dose: 10 mg / kg either direct slow IV or diluting with 100ml  of normal
saline at a rate of 1 ml/min followed by 1 mg/kg/hr infusion (or) 10mg
/kg thrice daily I.V.
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Mouth washes:
The drug available as mouth washes types and can be used in
haemophilia patients before and after dental extraction because saliva is
rich in plasminogen activator.
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MATERIAL AND METHODS
It is a prospective randomized case controlled study commencing
from December2012 to November 2013 (1year). 300 pregnant women
undergoing LSCS in R.S.R.M lying in hospital were included in this
study.
In all the patients detailed medical and obstetric history was
taken. Vital parameters like heart rate, respiratory rate and blood
pressure were checked. Preoperative basic investigations were done.
General and obstetric examination was done for all patients.
Gestational age was confirmed by USG. All 300 patients were allocated
into two groups 150 patients in the study group and 150 patients in the
control group. All patients were counselled and informed consent
obtained.
Study Group:-
? One gram tranexamic acid (10ml) in 100ml NS over 10
minutes 20 minutes before the skin incision.
? Inj. Oxytocin 10 U intramuscularly after the delivery of baby
and 10Uadded into intravenous infusion.
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Control Group:-
? Placebo injection of 100ml normal saline over 10minutes 20
minutes prior to skin incision.
? Inj.oxytocin 10U intramuscularly after the delivery of baby
and 10U   added to intravenous infusion.
Inclusion Criteria
Primi  and 2ndgravida with term live singleton pregnancy being
delivered by LSCS.
Exclusion Criteria
? Multiple pregnancy
? Pre eclampsia
? Macrosomia
? Prev. H/o caesarean delivery
? Polyhydramnios
? Those requiring blood transfusion due to anaemia
? Fibroid complicating pregnancy
? Placental abnormalities like
 Placenta previa
 Abruptio placenta
 Placenta accreta, increta, percreta,
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? H/o bleeding disorders
? Persons allergic to tranexaneic acid
? Associated systemic complication involving Heart, Liver and
Kidney
? Prev. H/o PPH
? Prolonged and obstructed labour
? Gravidity more than 3.
Methods:-
Study and control group patients received the injection as
mentioned above.  All the LSCS were done under spinal anaesthesia.
The following parameters were monitored in all the cases.
Preoperative pulse rate, blood pressure, respiratory rate was
monitored. Haemoglobin and haematocrit was done.
Vital Signe: pulse rate, respiratory rate, blood pressure were checked
immediately after placental delivery and 1hour and 2hours after surgery.
? Blood was collected and estimated for two periods following
placental delivery to end of surgery and from end of surgery to
2hrd postpartum.
? Uterine contractility.
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? Neonatal manifestation.
? Side effects caused by tranexamic acid
? Post-partumHb% haematocrit were checked after 48 hours.
? Maternal blood transfusion, need for the additional uterotonics
were noted.
Measurement of blood loss:
? Blood collected separately in the kidney tray and soaked with
swabs were weighed from placental delivery to 2hrs post
partum.
? Amniotic fluid and bleeding occurred prior to placental
delivery was ignored.
                                   Swab weight                Swab weight
Total blood loss =                               -
     After Delivery            before Delivery
1gm of swab weight = 1ml of blood (Bonica et al 1951)
After collecting all the data the data were tabulated in a master
chart and analysed. The data were analysed by using the statistical
package for social science (SPSS) version 11.5.  Normality of
distributionwas checked as needed. The results were expressed as
frequency, mean plus or minus standard deviation and median.
Statistical comparison was carried out using chi square test(x2) test,
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independent t test, or mann-whitney test, and paired t test where
appropriate. Equal variance assumption was assessed by the levene test.
Two tailed P<0.05 was considered significant.
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RESULTS AND ANALYSIS
This is a prospective randomized case controlled study
commencing from December 2012 to November 2013. 300 women
undergoing LSCS in R.S.R.M. Lying in Hospital Stanley Medical
College were included in this study. 150 women comprised study group
subject who received tranexamic acid and 150 women comprised
control group subject who did not receive tranexamic acid.
TABLE -1
DISTRIBUTION OF CASES ACCORDING TO AGE GROUP
Age in years
Number of cases
Study Group Control Group
Number % Number %
< C20 9 6% 9 6%
20 – 24 71 47.3% 82 54.7%
25 – 29 62 41.7% 50 33.3%
>30 8 6% 9 6%
Table – 1 Shows distribution of cases according to age group.
Majority of the patients (50%) inboth groups were 20 – 24 years and 6%
of the patients belong to < 20 and > 30 yrs.
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TABLE – 2
OBSTETRIC FORMULAS
Obstetric
formula
Number of Cases
Study Group Control Group
Number % Number %
Primi 120 80% 110 73%
2ndgravida 30 20% 40 27%
Chi Square (x2) = 1.863 P = 0.172 (NS)
Table – 2 shows distribution of cases according to parity in both
groups. There is no statistical significance between these two groups
TABLE – 2
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TABLE – 3
DISTRIBUTION BASED ON SUBJECTIVE CHARACTERS
Height &
Weight
Study Group Control Group P
Mean S.D Mean S.D
Weight
(Kg) 51.90 1.263 51.95 1.166 0.704 (NS)
Height
(cm)
151.89 3.051 152.38 1.230 0.67 (NS)
Table – 3 Shows confounding factors like height and weight are
comparable in both groups. Mean weight was 51.90 kg in study group
and 51.95 in control group(P=0.704). The difference in weight in both
groups was not statistically significant.
Mean height was 151.89 cm is study group compared to 152.38
cm is control group(P=0.67). The difference in height was not
statistically significant. Both the groups were comparable.
TABLE-3
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TABLE – 4
DISTRIBUTIONS OF CASES ACCORDING TO INDICATION
OF LSCS
Indication of LSCS
Study Group
(No. of cases)
Control Group
No. of cases
Foetal distress 49 54
Failed Induction 20 15
Cephalic pelvic 38 45
Breech 15 11
Severe
oligohydraminos
14 13
PROM  with Failure to
progress
14 12
Chi – Square (x2) = 2.354
P value = 0.798 [Statistically not significant]
Table – 3 Shows distribution according to indication of LSCS in
both groups. The indication can have an effect on amount of
intraoperative blood loss. The indications for LSCS were comparable in
both the groups.
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TABLE – 5
VITAL SIGNS BEFORE DELIVERY
Study Control
P ValueMean S.D Mean S.D
Pulse rate(bpm) 82.14 1.264 82.02 2.005 0.536
(NS)
Respiratory rate
(breath/min)
18.25 0.779 18.33 1.059 0.107
INS)
Systolic BP (mm Hg) 119.29 3.592 118.93 3.086 0.362
(NS)
Diastolic BP (mm
Hg)
79.03 2.854 78.47 3.714 0.382
(NS)
Table – 5 Shows preoperative vital signs like Pulse rate, systolic
and diastolic blood pressure and respiratory rate. There was no statically
significant difference between both groups. Preoperative vitals were
comparable in both the groups.
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TABLE – 6
EFFECT OF TRANEXAMIC ACID
Comparison of blood loss from the time of placental delivery to End
of Surgery
Study Control P Value
Mean S.D Mean S.D
Mean Blood Loss 305.38 56.2 371.30 104.5
0.001 **
Highly
significant
Table – 6 Shows blood loss from placental delivery to end of
LSCS. The blood loss was about 305.38 ml in study group and 371.30
ml in control group (P = 0.001) suggesting there was statistically highly
significant difference in blood loss between both groups. Those who
received Tranexamic acid had 65.92 ml less blood loss than who did not
receive the drug.
TABLE –6
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TABLE – 7
EFFECT OF TRANEXAMIC ACID
Comparison of blood loss from end of surgery to 2 hrs postpartum
Study Control P Value
Mean S.D Mean S.D
Mean Blood Loss 74.28 14.90 114.48 13.9
0.001 **
(HS)
Table – 7 Shows mean blood loss from end of surgery to 2 hours
post partum was 74.28 in study group and it was 114.48 ml in control
group (P = 0.001) suggesting there was statistically highly significant
difference in blood loss in both the groups. Patient who received
tranexamic acid had 40.2 ml less blood loss than who did not receive the
drug.
TABLE – 7
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TABLE – 8
EFFECT OF TRANEXAMIC ACID:
Comparison of blood loss from the time of placental delivery to 2
hours postpartum.
Study Control P
Mean S.D Mean S.D
Mean
Blood Loss
(ml)
379.66 70.73 485.45 116.16 0.001**
(HS)
Table -8  shows  mean  blood loss from placental  delivery  to 2
hours postpartum   was   379.66ml in the  study group  and   485.45 ml
in the  control  group(P =0.001)  suggesting  there was  statistically
highly  significant  difference  in blood  loss in both  the  groups. Patient
who received  the  drug had  106.12 ml  less  blood loss than  who  did
not receive the drug.
TABLE – 8
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TABLE – 9
EFFECT OF TRANEXAMIC ACID
Comparison of incidence of blood loss >500 ml
Study Control P Value
No of
cases
% No of
cases
%
Mean BL > 500ml 14 9% 29 19% 0.013
Mean BL < 500 ml 136 91% 121 81%
Table-9  shows  the incidence  of  blood loss  more  than  500ml
in both the  groups.  14women (9%) in the study group  had  blood  loss
more  than  500ml  compared  to  29 women (19%)   in the  control had
more than 500ml blood loss   P =0.013(S)  suggesting  statistically
significant  difference  in blood  loss in  both the groups.  Blood   loss
>500 ml  was  significantly  reduced in  tranexamic acid group  than
who did not received the drug.
TABLE – 9
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TABLE –10
Comparison of duration of surgery between the two groups
Study Control P Value
Mean S.D Mean S.D
Duration of LSCS
(min)
41.69 1.165 41.90 1.257 0.128
(NS)
Table – 9 Shows mean duration of surgery which was about 41.69
minutes in the study group and 41.90 in the control group(P=0.128).
Duration of surgery may influence the intra operative blood loss. There
was no statistically significant difference in the duration of surgery
between the groups.
TABLE –10
COMPARISON OF DURATION OF SURGERY
BETWEEN THE TWO GROUPS
41.6941.90
Duration of LSCS (min)
Study
Contro
l
62
TABLE – 11
Vital signs at the time of placental delivery in both the groups.
Study Control P Value
Mean S.D Mean S.D
Pulse rate (bpm) 85.19 1.161 85.35 1.622 0.327
(NS)
Respiratory rate
(Breath/min)
18.34 0.918 18.45 0.671 0.252
(NS)
Systolic BP
(mmHg)
118.59 5.971 118.67 2.376 0.879
(NS)
Diastolic BP
(mmHg)
76.30 4.19 75.77 2.94 0.209
(NS)
Table – 11Shows mean pulse rate, respiratory rate, systolic and
diastolic blood pressure at the time of placental delivery in both the
groups. There was no statistically significant difference in vital signs at
the time of placental delivery in both the groups.
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TABLE – 12
VITAL SIGNS 1 HR AFTER SURGERY
Study Control P
Value
Mean S.D Mean S.D
Pulse rate (bpm) 84.09 1.652 83.97 1.114 0.437
(NS)
Respiratory rate
(Breath/min)
18.49 0.873 18.43 0.901 0.558
(NS)
Systolic BP
(mmHg)
119.56 2.197 119.67 3.116 0.716
(NS)
Diastolic BP
(mmHg)
80.77 2.306 80.26 3.780 0.157
(NS)
Table – 11 Shows mean pulse rate, systolic and diastolic blood
pressure and respiratory rate 1 hour after surgery in study and control
groups. There was no statistically significant difference in the vital signs
1 hour after surgery in both groups.
TABLE – 12
VITAL SIGNS 1 HR AFTER SURGERY
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TABLE – 13
VITAL SIGNS 2 HRS AFTER SURGERY
Study Control P Value
Mean S.D Mean S.D
Pulse rate (bpm) 81.62 1.899 81.69 1.362 0.727
(NS)
Respiratory rate
(Breath/min)
18.40 0.927 18.37 0.879 0.798
(NS)
Systolic BP
(mmHg)
120.97 5.559 120.84 4.45 0.819
(NS)
Diastolic BP
(mmHg)
80.09 2.560 79.92 3.791 0.643
(NS)
Table – 12 Shows mean pulse rate, respiratory rate, systolic and
diastolic blood pressure at 2 hours after surgery in both the groups.
There was no statistically significant difference in vital signs at 2 hours
after surgery in both the groups.
TABLE – 13
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TABLE-14
CHANGE IN BLOOD INDICES
Blood Indices
Study Control
P ValueMean S.D Mean S.D
Hb in gms Pre op
HB
Post op HB %
Change
9.767
8.762
- 1.00
0.2089
0.2195
9.788
8.237
- 1.551
0.1886
0.215 0.001**
(HS)
PCV(%) Pre op
PCV
Post op PCV
change
28.83
27.85
-0.98
0.999
1.006
28.91
26.62
-2.29
0.948
1.235 0.001**
(HS
Table – 13 Shows comparison of mean fall of haemoglobin
andhaematocrit in both the groups. Mean fall of haemoglobin was 1.00
in the study group and 1.55 in the control group. Mean fall of
haematocrit was 0.98 in study group and 2.29 in control group.
Mean fall of postoperative haemoglobin and haematocrit was
significantly reduced in study group than control group.(P=0.001) There
was  statistically highly significant difference in both the  groups.
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TABLE – 15
ADDITIONAL UTEROTONICS
Additional Uterotonics
Study Control
Number % Number %
Yes 8 5% 18 12%
No 142 95% 132 88%
Chi – Square (X2) = 4.21
P Value = 0.04 (Significant)
Table – 15 Shows those who need additional uterotonics in both
the groups.Eight  patients  in the study group needed additional
uterotonics compared to 18 Patients in the control group. There was
statistically significant difference in both the groups.
TABLE – 15
ADDITIONAL UTEROTONICS
Yes No
8
18
132
Study
Control
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                                                TABLE – 16
COMPARISON OF BIRTH WEIGHT OF BABY
Birth weight of
Baby in kgs
Study Control
P
Mean S.D Mean S.D
0.226
(NS)
B.W. of Baby in
Kgs
2.841 0.122 2.806 0145
Table – 16 Shows mean birth weight of babies between study and
control groups. Mean birth weight was 2.806( kg) in control group and
2.841 kg in study group. There was no statistically significant difference
in birth weight in both the groups (P = 0.226). Both groups were
comparable.
TABLE – 16
COMPARISON OF BIRTH WEIGHT OF BABY
0.50
1.00
1.50
2.00
2.50
B.W. of baby (in kg)
2.841 2.806
Study
Control
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TABLE – 17
MATERNAL BLOOD TRANSFUSION
Blood Transfusion
Study Control
Number % Number %
Yes 2 1% 9 6%
No 148 99% 141 94%
Chi – Square cost = 4.624
P Value = 0.032 (S)
Table-17 shows number of patients those who needed blood
transfusion in both groups.9 Patients (6%) in the control group needed
blood transfusion compared to only 2 patients (1%) needed blood
transfusion.
There was statistically significant difference( P = 0.03) in both the
groups.
TABLE – 17
MATERNAL BLOOD TRANSFUSION
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Table – 18
ADVERSE DRUG REACTIONS IN BOTH THE GROUPS
Complication
Study Control
Number % Number %
Nausea 22 14% 17 11%
Vomiting 09 6% 14 .9%
Diarrhoea 01 0.5% 00
Signs of Thrombosis 00 00
Chi square test X2?  2.73, P Value: 0.435 (NS)
Table – 17 Shows adverse drug reactions Nausea, Vomiting,
diarrhoea occurred in 22,9,1 cases in the study group and in the control
group 17,14,0 cases respectively.
There was no statistical difference in adverse reaction between
study and control group suggesting tranexamic acid has no significant
adverse drug reaction. There is no increase incidence of thrombosis in
this study
Table – 18
ADVERSE DRUG REACTIONS IN BOTH THE GROUPS
0
5
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Nausea Vomiting Diarrhea Signs of
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0
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TABLE – 19 APGAR SCORE
COMPARISON OF APGAR IN BOTH THE GROUPS
Apgar Score
Study Control
Number % Number %
? 8/10 145 97% 148 99%
< 8/10 5 3% 2 1%
Chi – Square (X2) test = 1.316
P value = 0.251
Table 18 Compares the APGAR Scores between study and
control groups. There was no statistically significant difference in the
Apgar score between study and control groups and the APGAR Scores
was not adversely affected by the drug
TABLE – 19 APGAR SCORE
COMPARISON OF APGAR IN BOTH THE GROUPS
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DISCUSSION
Caesarean section is one of the most frequently performed
obstetric surgery all over the world8(Ramadani et al). Maternal mortality
and morbidity is increased due toincreased blood loss during caesarean
section.
During placental delivery the fibrinolytic system gets activated
and fibrinogen and fibrin are rapidly degraded. These effects can last up
to 6-10 hrs postpartum causing more bleeding.
Tranexamic acid is an anti fibrinolytic and its use appears to
reduce blood loss during caesarean section. Reducing operative blood
loss would reduce the need for blood transfusions and also reduces the
post partum anaemia which is a major cause of maternal morbidity and
makes the women more vulnerable to major PPH in future pregnancies.
Hence, we decided to use tranexamic acid  prophylactically, a cost
effective drug  in our study and observe its efficacy and safety in
reducing blood loss during and after caesarean section.
1) Maternal Age:-
In our study the age groups were distributed from 18 to 35 years
of age. Maximum percentage of patients belongs to 20-24yrs of age of
which 47% in the study group and 55% in the control group.In a study
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conducted at Lyari general hospital Karachi from March 2009 to April
2011 the mean age was 24yrs.
2) Obstetric Formula:-
In our study primigravidas are more in both groups than second
gravidas. In study group 80% were primigravidas 20% were second
gravidas. In control group 73% were primigravidas and 27% were
2ndgravidas. Similarly study conducted by Ming-YingGai et al at peking
union medical college hospital, Beijing 2004, 180 pregnant women were
included in their study, majority are primigravidas.
3) Subjective Characters:-
In our study mean height was 151.89cm in the study group,
152.38 cm in the control group. Mean weight was 51.90kg in study
group 51.95kg  in control group.In Similar study conducted by Patel
purvi and Gohelmayur et al at SSG Medical College  Hospital, Baroda,
Gujarat the mean height was 152.57cm and mean weight was 49.64cm.
4) Indication for LSCS:-
In our study  the maximum percentage of LSCS was done for
foetal distress which accounts for 33% in the study group and 36% in
the control group, second major is the cephalopelvic disproportion
which accounts for 25% in the study group and 30% in the control
group, failed induction 14% in the study group and 10% in the control
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group, Breech presentation 10% in the study group 7% in the control
group, severe oligohydramnios9% in the study group 9% in the control
group, PROM and failure to progress contributes 10% in the study
group and 7% in the control group. In a similar study conducted by Ali
Movafeghet al 2011 at Shariati hospital, University of Medical sciences,
and Tehran showed majority of the LSCS was for foetal distress,
cephalopelvic disproportion and for failure to progress.
5) Changes in vital parameters:-
In our study, mean pre operative vital parameters are comparable
in both the groups. The vital parameters which are monitored during the
time of placental delivery and 1 hour and 2hour were comparable in
both the groups. Similarly a study by A movafegh et al 2011 at Shariati
hospital Teharan vital signs were comparable, statistically no significant
difference in vital parameters  at the time of placental delivery 1hr, 2hrs
after surgery. Similarly Goelmayur etal 2007, atSSG medical college
hospital, Baroda there was no statistically significant difference in heart
rate, respiratory rate and blood pressure during, immediately after
placental delivery 1hr and 2hrs postpartum.
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6) Blood Loss:-
Our study showed mean blood loss from placental delivery to end
of surgery was 305.38ml in the study group and 371.30ml in the control
group. The mean blood loss from end of surgery to 2hrs
postpartumwas74.28ml in the study group and 114.48 in the control
group.The mean total blood loss from placental delivery to 2hrs
postpartum was 379.66 in the study group, 485.45ml in the control
group.
In a similar study by GohelMayar, Patel purvi, at Baroda medical
college hospital Gujarat 2007 showed that  blood loss from placental
delivery to end of surgery was 339.76ml in the control group and
299.21ml in the study group. Blood loss from end of LSCS to 2hrs
postpartum was 75.7ml in the study group and 133.03ml in the control
group. Total blood loss from placental delivery to 2hrs postpartum was
374.9ml in the study group and 472.79ml in control group.
? AfshanShahid et al – Lyari general hospital Karachi 2011
Blood loss from placental delivery to end of LSCS was 356.44 in
study group 710.22ml in the control group.
Blood loss from end of LSCS to 2hrs postpartum was 35.68ml in
the study group and 43.63ml in the control group.
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? Ali Movofegh et al – Shariati hospital Tehran 2011.
Blood loss from placental delivery to end of LSCS was 262ml in
the study group and404ml in the control group.
Blood loss from end of LSCS to 2hrs postpartum was 67.1ml in
the study and 141ml in the control group. These results were
comparable with our study.
7) Incidence of blood loss >500ml
Our study showed, fourteen members 9% in the study group had
blood loss >500ml compared to 29 members 19% in the control group.
Similarly GoelMayur et al at SSG medical college hospital,
Baroda blood loss >500ml was 10% in the study group and 28% in the
control group.
? Zheng et al, Teaching hospital of Beijing 2011, Blood loss more
than 400ml was significantly  reduced by tranexamic acid during
normal vaginal delivery.
? Gai, Wu et al, Peking union medical college hospital, Beijing
Blood loss more than 500ml was significantly reduced by
tranexamic acid during and after caesarean section.
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? Bresnoc K et al, observed that tranexamic acid significantly
reduces the blood loss and  the incidence of postpartum
haemorrhage in vaginal delivery.
8).Changes in blood in dices.
Our study showed mean postoperative fall of haemoglobin was
about 1gm% in the study group and 1.551gm% in the control group.
? Afshanshahid et al, Lyari hospital Karachi 2011.
 Mean fall of haemoglobin was 1.09 in the tranexamic acid group,
and 1.88gm% in the control group
 Mean fall of post operative haematocrit was 1.89 in the
tranexamic acid group, and 4.30 in the control group.
? Ali Movafegh et al 2011. Iran
 Mean fall of postoperative haemoglobin was 1.0gm% in
tranexamic acid group and 1.8gm% in the control group.
? SanjanaHalder et al 2013. India
 Mean fall of haemoglobin value was1.214gm% in the tranexamic
acid group and 1.7256gm% in the control group.
 These results were comparable with our study.
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9) Additional Uterotonics:-
In our study, additional uterotonics were needed in 5% of the
patients in the study group and 12% in the control group.
? Gungorduk et al, Mardin women’s hospital Mardin, additional
uterotonics were needed in 4% of tranexamic acid group and
8.5% in the control group.
? Ali Movafegh et al 2011  Additonal uterotonics use were
significantly reduced in tranexamic acid group patients.
These results were comparable with our study.
10)  Maternal blood transfusion:-
In our study, maternal blood transfusion was 1% in the
tranexamic acid group and 6% in the control group.
The results were same in a similar study conducted by the
division of obstetrics and Gynecology, University of Oslo, Norway in
2000.
11). Duration of Surgery:-
Our study showed, mean duration was 41.69 minutes in the
tranexamic acid group and 41.90 minutes in the control group.
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Shahid et al Dow University of Health Sciences,  mean duration
of surgery was  45 to 50 minutes in all patients  and Ali movafegh et
al,mean duration of surgery was 40.2 in all the patients.
12). Maternal Complications:-
The side effects of tranexamic acid nausea, vomiting, diarrhoea
were not statistically significantin both the groups in our study. The
incidence of thrombosis was not reported in our study but still more
number of patients need to be observed for its occurrence.
13).APGAR Score:-
APGAR score was comparable in both the groups. In our study
there is no statistically significant difference in both the groups. These
results were comparable with previous studies.
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SUMMARY
* The study was conducted in the department of obstetrics and
Gynaecology, R.S.R.M. Lying in hospital, Stanley medical
college, Chennai to clinically observe the blood loss during and
after caesarean section.
 * 300 patients were selected for the study. 150 patients were
included in the study group. 150 patients were included in the
control group.
* The possible confounding factors like age, height, weight and
gravidity were comparable in both the groups.
* Distribution of cases with respect to indication of LSCS likefoetal
distress, cephalo pelvic disproportion, failed induction, breech,
Severe oligohydramnios, PROM with failure to progress were
comparable in both the groups.
* Study group showed significant decrease in amount of blood loss
from time of placental delivery to 2hrs postpartum around
(106.12ml)
* Study group showed significant decrease in blood loss from time
of placental delivery to end of surgery (around 65.92ml)
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* Study group showed significant decreases in blood loss from end
of surgery to 2hrs postpartum (around 40.2ml)
* The incidence of blood loss >500ml was significantly reduced in
study group than control group 9% study group, 19% in the
control group.
* Postoperative fall of haemoglobin significantly reduced than
control group
* Postoperative fall in haematocrit values are significantly reduced
in study group compared to control group.
* There was no significant difference in the vital signs in both the
groups from the time of placental delivery to 2hrs postpartum.
* There was no significant difference in birth weight, duration of
surgery and APGAR scores.
* The need for blood transfusion and additional uterotonics were
significantly reduced in tranexamic acid group.
* The incidences of adverse effects such as nausea vomiting,
diarrhoea were not increased in study group and the incidence of
thrombosis was not increased with the use of tranexamic acid.
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CONCLUSION
Intravenous tranexamic acid when given prophylactically 20
minutes before skin incision appears to reduce the amount of blood loss
during and after caesarean section.Hence it can be recommended for
reducing blood loss in caesarean section. Tranexamic acid was not
associated with any adverse perinatal outcome.
It did not have much maternal side effects.  Some  studies
observed that  tranexamic acid  minimally  increases the  risk  of
thromboembolism  which was  not  observed  in  our  study.   Further
studies are necessary to evaluate the efficacy in pregnancies at high risk
for PPH.
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ABBRIVIATIONS
LSCS - Lower Segment Caesarean Section
DIC - Disseminated intravascular coagulation
HELLP - Haemolysis, Elevated liver enzymes, Low
platelets.
ITP - Idiopathic Thrombocytopenic purpura
APGAR - Appearance, Pulse, Grimace, Activity,
Respiration
IUFD - Intra Uterine Foetal Death.
HB - Haemoglobin
PPH - Post Partum Haemorrhage
LFT - Liver Function Test
RFT - Renal Function Test
BT - Bleeding Time
CT - Clotting Time
PROFORMA
Name Age IP No.
LMP:                                                   Gestational age
EDD: Date of Delivery
DOA:
DOD:
Obstetric Formula:
Complaints:  Pain,                   Bleeding P/V,                        LeakingP/V
MENSTRUAL HISTORY:              R/IR
MARITAL HISTORY:                   Consanginous/Non-Consanginous
OBSTETRIC HISTORY:
S.No. GA at
Birth
LCB Mode of
Del
Birth wt Place
PRESENT PREGNANACY:
Booked Immunised                  Complications
PAST HISTORY:
H/O HT            DM                BA            PT
H/O Bleeding disorders
H/O Allergy
PERSONAL HISTORY:
Sleep
Appetite
Bladder and Bowel   habits
FAMILY HISTORY: HTN/DM/BA/PT
GENERAL EXAMINATION:
HT:
WT:
Pallor:
Pedal edema:
Temp:
Pulse:
BP:
CVS:
RS:
Breast:
Thyroid:
PER ABDOMINAL EXAMINATION:
PER VAGINAL EXAMINATION:
Time of
Administra
tion of
drug
Time of
BabyDeli
very
Indicatio
n for C.S
Birth
Weight of
Baby
Blood loss
from Placenta l
delivery to end
of surgery
Blood loss From
End of Surgery
to hours Post
Partum
INVESTIGATIONS:
HB
PCV
URINE R/E
BLOOD SUGAR, UREA, CREATININE
BT, CT
BLOOD GROUPING AND TYPING
LIVER FUNCTION TEST
S. BILIRUBIN
SGOT
SGPT
SAP
REMARKS
1. Blood loss from delivery of placenta to end of surgery
2.  Blood loss from end of surgery to 2 hours post partum
3.  Maternal complications
4. Post operative haemoglobin and haematocrit
5.  Need for additional uterotonics and blood transfusion.
6. Neonatal status
7. Side effects of drug
CONSENT FORM
STUDY TITLE : “EFFICACY AND SAFETY OF TRANEXAMIC
ACID IN REDUCING BLOOD LOSS DURING
AND AFTER  CAESAREAN SECTION”.
STUDY CENTRE      : R.S.R.M. Lying in Hospital, Stanley Medical College,
Chennai.
PARTICIPANT NAME : AGE:  SEX: J.D.NO.
I confirm that I have understood the purpose of procedure for the above
study, I have the opportunity to ask the question and all my questions and doubts
have been answered to my satisfaction.
I understand that the investigator, regulatory authorities and the ethics
committee will not need my permission to look at my health records both in respect
to the current study and any further research that may be conducted in relation to it,
even if I withdraw from the study.  I understand that my identity will not be revealed
in any information released to third parties of published, unless as required under the
law.  I agree not to restrict the use of any  results that arise from the study.
I hereby consent to participate in this study of  :
“EFFICACY AND SAFETY OF TRANEXAMIC
ACID IN REDUCING BLOOD LOSS DURING AND
AFTER  CAESAREAN SECTION”
Place : Signature of Investigator:
Date  : Study Investigators Name
Institution : Signature / Thumb Impression of patient
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1 Anandhi 19 1935 Primi 155 53 82 122/80 18 9.60 28 41 F.I 2.84 No no 86 120/74 18 85 128/80 19 84 126/80 19 8.6 27 No N no
2 Nirmala 24 1321 G2P1L1 151 52 83 126/78 19 9.60 28 42 S.O 2.78 No no 85 110/80 18 86 121/82 19 78 126/78 19 8.6 27 No V no
3 Sathya 20 105 Primi 150 50 81 120/80 19 9.80 29 42 CPD 2.83 No no 86 118/80 18 80 118/86 18 88 126/80 19 8.8 28 No no no
4 Sumathy 21 185 Primi 151 51 82 118/78 19 9.80 29 42 PFtoP 2.82 No no 84 116/70 19 86 120/80 19 82 120/76 19 8.8 28 No no no
5 Shobana 23 430 Primi 152 53 82 126/78 17 10.20 31 41 F.D 2.80 No no 85 118/70 20 83 118/86 18 81 120/76 19 9 30 No no no
6 Sunitha 22 152 Primi 153 50 80 124/78 18 10.20 31 39 PFtoP 2.85 Y no 85 120/80 19 81 120/80 19 84 120/76 18 9 30 No no no
7 Bhakiam 30 383 Primi 152 54 84 118/78 19 10.20 31 42 F.D 2.80 No no 86 118/82 18 83 120/84 19 84 120/78 19 9.2 30 No no no
8 Monisha 18 75 Primi 151 52 82 124/78 19 10.00 30 44 PFtoP 2.79 No no 87 120/82 17 84 118/82 18 83 120/80 19 9 29 No no no
9 Dhanalakshmi 22 480 Primi 120 53 83 118/80 19 9.80 29 42 F.I 2.81 No no 85 118/84 19 83 120/86 19 80 124/78 18 8.8 28 No no no
10 Revathy 26 530 Primi 153 51 81 124/78 19 9.60 28 43 Breech 2.91 No no 86 120/80 18 81 118/84 18 81 124/78 18 8.6 27 No no no
11 Lavanya 27 184 G2P1L1 151 52 80 124/78 18 9.60 28 41 CPD 2.93 No no 86 118/76 19 83 120/80 19 82 120/80 17 8.6 27 No no no
12 KamalaKani 20 98 Primi 155 53 79 124/78 16 9.80 29 43 CPD 2.78 No no 86 118/78 18 81 118/84 19 78 126/86 18 8.6 28 No no no
13 Gunasundari 28 89 Primi 151 51 84 124/80 17 9.60 29 42 Breech 3.00 No no 85 118/76 19 84 118/80 18 84 124/80 19 8.6 28 No no no
14 Banumathy 30 280 G2P1L1 152 53 83 124/78 18 9.80 29 42 F.D 2.83 No no 86 120/70 19 81 120/80 19 84 124/78 19 8.8 28 No no no
15 Kala 25 338 Primi 151 52 82 118/80 19 9.60 28 42 CPD 2.81 No no 86 118/74 18 83 120/82 20 82 124/78 18 8.6 27 No no no
16 Suganya 21 375 Primi 153 51 81 120/78 17 9.60 28 43 F.D 2.82 No no 85 112/70 17 84 120/86 19 80 124/80 19 8.6 27 No no no
17 Haritha 25 414 Primi 152 52 82 121/80 18 9.80 29 42 PFtoP 2.81 No no 86 114/74 18 83 120/80 17 79 120/80 19 8.8 28 No no no
18 Lakshmi 22 459 Primi 152 53 80 118/80 19 10.00 30 41 F.D 2.80 No no 87 120/76 19 85 120/78 18 80 120/80 18 9 29 No no no
19 Preetha 30 502 G2P1Lo 154 54 82 118/80 19 9.80 29 42 F.D 2.87 No no 85 128/72 20 86 120/82 19 82 120/80 18 8.8 28 No no no
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20 Jansirani 26 476 Primi 155 52 83 116/78 18 9.60 28 43 F.D 2.90 Y no 87 118/76 19 86 120/81 19 83 120/80 17 8.6 27 No no no
21 Dhivya 18 501 Primi 151 50 82 118/76 18 9.60 28 42 S.O 2.65 No no 86 120/82 20 85 120/78 20 84 120/80 17 8.6 27 No no no
22 Shobana 23 548 Primi 150 53 83 117/78 19 9.60 28 41 F.D 2.72 No no 84 122/70 19 85 118/80 19 84 124/80 19 8.6 27 No no yes
23 Sridevi 27 639 G2P1L1 151 51 82 118/80 19 9.80 29 41 PFtoP 2.85 No no 85 129/70 18 86 118/76 18 82 120/80 19 8.8 28 No N no
24 Kudia Devi 21 636 Primi 149 50 84 120/78 18 9.80 29 42 S.O 2.65 No no 86 118/76 18 81 118/80 19 84 120/80 19 8.8 28 No no no
25 Dishath 30 717 Primi 150 51 80 120/80 19 9.80 29 42 CPD 2.83 Y no 86 120/76 18 81 120/80 19 81 124/80 19 8.8 28 No no no
26 Mala 25 828 Primi 151 51 81 118/78 18 9.60 28 41 CPD 2.85 No no 85 118/78 19 83 120/80 18 82 129/80 19 8.8 27 No V no
27 Elavarasi 21 922 G2P1L1 151 51 81 120/80 18 9.60 28 43 S.O 2.85 No no 85 120/76 19 85 120/80 18 83 121/84 19 8.6 27 No V no
28 Sumathy 19 976 Primi 152 54 80 118/78 19 9.60 28 42 Breech 2.95 No no 84 118/78 19 85 120/82 17 81 121/88 19 8.6 27 No no no
29 Kalaiselvi 25 944 Primi 154 52 83 120/78 19 9.80 29 42 F.D 2.90 No no 86 118/76 18 84 120/84 18 84 110/80 18 8.8 28 No N no
30 Mahalakshmi 22 1008 Primi 150 50 82 120/76 19 9.80 29 42 F.I 2.75 No no 85 120/76 17 86 120/80 19 78 120/76 17 8.8 28 No no no
31 Savithri 26 771 Primi 152 52 83 120/80 18 9.60 28 41 F.D 2.95 No no 84 120/72 19 87 118/76 19 84 120/80 18 8.6 27 No no no
32 Rinomaria 23 1052 Primi 151 51 82 118/78 17 9.60 28 41 CPD 2.68 No no 86 118/72 20 83 118/78 18 81 124/78 19 8.6 27 No no no
33 Vijaya 30 948 G2P1L1 153 53 81 120/76 16 9.60 28 42 F.D 2.95 Y no 84 120/70 16 87 118/80 19 78 126/78 19 8.6 27 No no no
34 Muthumary 27 1141 Primi 152 51 82 118/78 17 9.80 29 41 Breech 2.80 No no 84 116/72 19 84 118/78 18 80 124/84 18 86 28 No no no
35 Uma 20 1203 Primi 153 54 84 120/76 17 10.00 30 40 CPD 2.78 No no 86 118/72 19 85 118/76 17 82 120/80 17 8.8 29 No no no
36 Maheswari 28 984 Primi 151 52 82 118/78 18 10.20 31 42 S.O 2.75 No no 85 116/82 18 86 114/78 17 80 126/80 18 9 30 No no no
37 Nalini 19 1362 Primi 152 50 81 118/80 19 10.00 30 43 CPD 2.85 No no 84 118/70 17 86 118/80 18 81 121/80 19 9.2 29 No N no
38 Barkavi 23 1221 Primi 152 53 82 120/80 19 9.60 28 42 CPD 2.40 No no 84 120/72 18 86 116/78 19 82 116/80 19 9 27 No yes no
39 Bindia 23 1376 G2P1L1 153 51 83 118/80 18 10.00 30 41 FI 2.90 No no 85 118/76 19 83 118/80 18 83 118/82 18 8.6 29 No no no
40 Pencillammal 26 1458 Primi 150 52 82 118/70 18 10.20 31 42 PFtoP 2.78 Y no 86 117/80 19 83 120/80 19 79 120/84 19 9 30 No no no
41 Narmadha 20 1491 Primi 154 52 82 120/80 19 9.60 28 41 F.D 2.85 No no 86 124/76 18 83 116/82 19 80 118/80 20 9 27 No no no
42 Roja 25 1480 Primi 153 53 80 122/84 19 9.80 29 42 CPD 2.80 No no 85 112/74 19 86 120/82 18 81 120/82 16 8.6 28 No no no
43 Selvi 21 1733 Primi 154 51 81 118/78 17 9.60 28 41 Breech 2.89 No no 86 116/76 18 84 116/82 19 82 120/76 17 8.8 27 No N no
44 Padma 25 1290 Primi 151 53 82 120/80 19 9.60 28 41 CPD 2.80 No no 85 120/80 17 84 120/80 19 84 118/82 19 8.6 27 No no no
45 Jansirani 26 1833 Peimi 152 54 82 121/80 18 9.80 29 42 F.D 2.95 No no 84 120/76 17 86 118/78 18 81 116/78 19 8.6 28 No no no
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46 Radhika 22 1846 Primi 153 51 81 118/78 18 9.60 28 42 CPD 2.85 No no 84 116/74 18 84 120/82 18 83 118/78 19 8.8 27 No no no
47 Parveen 27 1655 G2P1Lo 153 50 80 120/86 18 9.80 29 44 CPD 2.75 No no 85 114/76 19 86 118/82 17 82 118/80 18 8.6 28 No no no
48 Kanchana 24 2075 Primi 151 52 84 110/80 18 9.60 28 45 F.D 2.80 No no 86 120/76 19 84 116/80 18 80 120/78 19 8.6 27 No no no
49 Sangeetha 25 2506 Primi 153 52 82 120/80 18 9.80 29 38 CPD 2.95 No no 85 118/76 18 86 120/82 19 78 120/78 19 8.8 28 No N no
50 Aabitha 18 2170 Primi 152 51 84 118/76 19 9.60 28 44 CPD 2.87 Y yes 86 118/70 17 83 118/80 18 81 120/80 20 8.6 27 Yes no no
51 Punithavalli 26 2246 G2P1L1 151 50 82 120/78 19 9.80 29 41 S.O 2.83 No no 86 116/70 18 83 118/80 19 82 120/78 19 8.8 28 No V no
52 Gayathri 21 2244 Primi 151 50 82 120/80 19 9.80 28 44 S.O 2.55 Y yes 85 116/70 19 85 120/80 19 81 120/81 19 8.6 27 No no no
53 Shanthi 25 2351 Primi 153 54 83 118/76 19 9.80 28 40 Breech 2.95 No no 85 121/70 18 85 124/82 19 82 120/76 20 8.6 27 No N no
54 Sherin Banu 20 2371 Primi 154 52 84 120/80 19 9.80 29 41 F.I 2.75 No no 86 118/76. 19 84 124/86 17 78 120/80 20 8.6 28 No no no
55 Chitra 26 2365 G2P1L1 155 53 85 110/80 18 9.60 28 42 CPD 2.80 No no 86 116/74 17 83 120/84 17 83 120/81 19 8.4 27 No no no
56 Anjalai 23 2494 Primi 153 50 82 114/76 19 9.80 29 44 F.D 2.85 No no 86 114/72 19 85 120/80 18 84 124/80 19 8.6 28 No no no
57 Shenbagam 28 2120 Primi 152 52 81 120/78 19 10.00 30 40 CPD 2.95 No no 84 115/70 20 84 120/82 19 81 124/80 19 8.7 29 No no no
58 Kousalya 30 1530 Primi 151 52 82 110/80 18 10.00 30 41 CPD 2.85 No no 84 114/74 17 85 120/82 19 84 124/80 18 9.1 29 No N no
59 Selvi 21 2610 Primi 150 51 83 120/86 19 9.80 29 42 CPD 2.75 No no 85 116/76 19 86 124/80 19 79 120/80 17 8.6 28 No no no
60 Mani Megalai 29 2516 G2P1L1 151 53 82 124/78 19 9.60 28 41 F.D 2.83 No no 86 120/72 20 84 126/80 18 84 120/80 18 8.8 27 No no no
61 Kavya 18 2618 Primi 153 52 82 122/88 18 9.80 29 44 Breech 2.85 No no 84 116/70 19 87 129/84 20 79 118/80 17 8.6 28 No no no
62 Vasantha Mary 20 2518 Primi 151 51 81 118/78 18 9.60 28 41 F.I 2.85 No no 84 117/72 17 87 120/82 17 81 120/80 19 8.6 27 No V no
63 Rajeshwari 25 2716 Primi 154 53 82 118/78 17 9.60 28 38 F.D 2.95 No no 84 117/72 19 81 129/82 17 79 118/80 19 8.6 27 No no no
64 Sasikala 23 2815 Primi 153 54 82 116/74 18 9.80 29 41 PFtoP 2.90 Y yes 86 118/70 18 84 120/80 18 80 120/80 17 8.8 28 No no no
65 Nadhiya 27 2835 G2P1L1 154 51 82 120/80 19 9.60 28 40 F.D 2.95 No no 84 120/70 17 85 118/82 20 79 120/82 20 8.6 27 No no no
66 Ammu 22 3810 Primi 152 52 83 110/78 19 10.20 31 41 CPD 2.83 No no 84 121/72 18 85 120/80 19 84 120/80 19 9.1 30 No N no
67 Sumathy 25 2995 Primi 150 51 84 120/80 18 10.20 31 42 F.D 2.85 No no 85 122/70 17 86 118/82 19 81 118/80 19 9.1 30 No no no
68 Usha 25 2701 Primi 151 53 82 110/78 19 10.00 30 41 Breech 2.83 No no 86 120/76 18 83 120/80 19 82 124/84 18 8.9 29 No no no
69 Sulthana 21 2718 Primi 154 54 82 114/76 17 9.60 28 42 F.I 2.90 No no 86 121/77 18 81 118/80 19 83 120/76 19 9.1 27 No no no
70 Durga 27 3052 G2P1Lo 151 53 81 120/80 18 9.80 29 39 S.O 2.85 No no 87 118/74 17 84 120/80 20 79 120/82 20 8.8 28 No no no
71 Rekha 26 3104 Primi 150 52 82 122/78 18 9.60 `28 41 PFtoP 2.80 No no 85 114/72 18 83 120/74 17 80 124/84 19 8.6 27 No no no
70
68
71
70
71
281 72 353
288
290
289
301
548
289 70 359
290 68 358
291 71 362
357
361
357
359
560 160 720
288 71 359
357
288
289
288
287
71
72
69
288 69
450 98
356
289 67 356
287 69 356
289 71 360
361
291 72 363
496 124 620
290 69 359
359
288 72 360
288 69 357
285 70 355
372
302 69 371
72 Sakunthala 25 12175 Primi 151 51 81 120/78 19 10.00 30 44 F.D 2.95 No no 84 116/70 18 81 120/80 17 81 124/78 19 8.6 29 No no yes
73 Yasmin 22 12217 Primi 152 52 80 118/70 17 10.20 31 41 F.D 2.85 No no 84 114/72 19 86 118/82 18 82 122/78 20 9.1 30 No N no
74 Chinnammal 25 12697 Primi 151 53 82 120/80 18 9.80 29 41 CPD 2.83 No no 84 112/74 19 86 120/82 18 83 126/86 18 8.8 28 No no no
75 Sasikala 23 12723 Primi 153 54 83 118/78 18 9.60 28 42 F.I 2.85 No no 85 116/70 20 83 118/78 19 84 124/78 19 8.6 27 No no no
76 Rekha 22 12735 G2P1L1 154 50 82 120/80 19 9.80 29 39 F.D 2.85 Y yes 85 116/74 17 84 120/82 20 85 115/86 19 8.8 28 No no no
77 Ezhil 25 12437 Primi 151 52 80 120/80 19 9.60 28 41 Breech 2.95 Y yes 85 120/86 19 84 120/82 19 80 122/81 19 8.6 28 No N no
78 Inakia 20 12690 Peimi 152 53 84 118/80 19 9.60 28 41 F.I 2.85 No no 86 118/78 19 84 118/82 18 81 124/84 19 8.6 27 No no no
79 Shalini 23 12685 Primi 151 52 82 120/80 19 9.80 28 42 S.O 2.73 No no 76 120/80 20 84 116/80 18 82 124/84 18 8.8 27 No no no
80 Poornima 30 12778 G2P1L1 154 54 83 118/80 18 9.60 28 41 CPD 2.83 No no 85 118/76 17 83 120/82 19 80 121/81 18 8.6 27 No no no
81 Veeralakshmi 26 12820 Primi 150 51 81 120/80 19 9.80 28 42 PFtoP 2.75 No no 86 120/82 17 84 120/80 19 84 119/79 19 8.8 27 No no no
82 Vijayalakshmi 22 12422 Primi 152 50 84 118/80 18 10.00 30 41 CPD 2.85 No no 86 118/76 18 85 118/82 19 81 118/76 20 9 29 No no no
83 Saritha 27 12834 Primi 151 52 80 116/80 19 10.20 31 42 F.D 2.95 No no 86 120/74 18 86 116/76 17 80 120/80 18 9 30 No V no
84 Devi 21 12804 Primi 153 53 82 120/86 19 9.60 28 41 Breech 2.88 No no 85 118/76 19 86 118/75 17 78 118/78 17 8.6 30 No no no
85 Suseela 25 12784 G2P1L1 150 53 83 124/78 18 9.80 29 42 F.I 2.78 No no 84 116/74 18 81 120/78 18 81 120/80 17 8.8 27 No no no
86 Priya 23 12335 Primi 152 50 84 118/78 19 9.60 28 41 F.D 2.75 Y yes 84 118/74 17 84 115/80 18 83 118/76 18 8.6 28 No N no
87 Devi 26 12559 Primi 153 52 82 130/78 18 9.60 28 42 CPD 2.85 No no 83 119/77 18 85 120/80 17 81 118/76 19 8.6 27 No no no
88 Selvi 21 12803 Primi 154 53 80 110/78 19 9.80 29 40 F.D 2.85 No no 86 120/76 19 85 118/82 17 84 120/78 19 8.8 27 No no no
89 Reena 18 12906 Primi 151 54 82 110/78 18 9.60 28 42 F.D 2.75 No no 85 118/78 18 86 120/84 20 79 118/76 18 8.6 28 No no no
90 Akila 23 12588 Primi 153 53 84 114/78 18 9.80 29 44 F.I 2.90 No no 85 120/72 19 86 120/80 19 83 116/78 17 8.8 27 No no no
91 Gayathri 27 12990 G2P1L1 152 51 82 120/86 19 9.80 29 42 PFtoP 2.95 No no 86 118/76 19 85 120/80 19 84 120/76 17 8.8 28 No no no
92 Nilaveni 21 13002 Primi 151 50 82 120/80 18 9.60 28 41 CPD 2.90 No no 86 116/76 18 83 118/84 18 81 118/78 18 9.6 28 No no no
93 Sundari 21 12660 Primi 150 52 83 122/84 19 10.20 31 42 F.D 2.85 No no 87 120/76 18 84 116/78 18 82 120/82 19 9.2 27 No N yes
94 Jayalakshmi 28 13037 Primi 151 54 82 120/78 19 9.60 28 42 S.O 2.75 No no 85 120/76 17 86 122/84 19 83 124/78 20 8.6 30 No no no
95 Nagalakshmi 24 13020 Primi 154 52 82 124/80 18 9.80 29 42 F.D 2.83 No no 84 120/74 17 86 122/84 19 84 122/84 17 8.8 27 No no no
96 Nagammal 25 13062 G2P1L1 153 51 83 120/80 19 9.02 27 42 FD 2.75 No no 86 116/76 20 84 120/82 20 80 124/80 17 8.4 28 No no no
97 Banupriya 26 13085 Primi 152 50 82 120/80 18 9.60 28 43 F.D 2.80 No no 85 118/70 19 80 120/80 17 79 126/78 18 8.6 27 No no no
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98 Manoja 20 12693 Primi 152 51 82 118/80 19 9.60 28 44 F.I 2.85 Y yes 86 116/76 18 85 120/80 17 81 120/80 17 8 27 yes no no
99 Thangamani 27 13118 G2P1L1 151 54 83 120/80 18 9.80 29 41 CPD 2.75 No no 85 114/77 19 85 120/82 18 84 120/82 17 8.8 28 No no no
100 Priya 21 12921 Primi 153 52 81 118/86 19 9.60 28 42 Breech 2.85 No no 86 115/80 20 84 120/80 18 82 120/82 18 8.6 27 No N no
101 Jayalakshmi 28 13357 Primi 150 53 80 120/80 19 10.00 30 42 CPD 2.95 No no 86 120/86 19 86 120/82 18 81 120/82 18 9 29 No V no
102 Umadevi 20 13454 Primi 152 51 80 118/80 19 9.60 28 40 PFtoP 2.85 No no 86 120/80 19 86 120/86 19 81 120/80 17 8.6 27 No N no
103 Amudha 26 13587 G2P1L1 151 52 82 120/80 19 9.80 29 42 F.I 2.95 No no 86 116/80 18 85 118/80 19 84 120/80 19 8.8 28 No no no
104 Uma 22 13514 Primi 152 52 82 120/78 19 9.60 28 43 F.D 2.75 No no 86 120/80 17 85 120/76 20 81 120/84 19 8.8 27 No no no
105 Chellammal 27 13529 Primi 153 53 81 112/80 19 9.60 28 41 S.O 2.68 No no 87 118/70 18 85 118/78 19 82 120/76 17 8.6 27 No no no
106 Jamilarani 23 13429 Primi 151 51 84 120/84 18 10.00 30 42 CPD 2.95 No no 85 120/76 17 83 120/78 18 83 118/78 17 9 29 No no no
107 Bharathi 24 13516 Primi 152 53 82 118/78 17 10.20 31 41 Breech 2.85 No no 85 120/82 17 83 118/76 18 80 120/80 18 9.2 30 No no no
108 Dahtchayani 30 13579 G2P1L1 152 50 83 120/76 18 9.60 28 42 F.D 2.95 No no 84 120/80 18 84 120/80 19 81 124/80 18 8.6 27 No no no
109 Malar 28 13532 Primi 153 52 81 120/78 19 9.60 28 43 F.I 2.90 Y yes 84 118/86 18 84 118/78 20 82 120/76 19 9.6 27 No no no
110 Gowthami 27 13586 Primi 154 51 80 118/78 19 9.80 29 42 F.D 2.85 No no 85 120/80 19 85 120/80 19 83 118/76 20 8.8 28 No no no
111 USha 20 13523 Primi 150 53 85 120/78 19 10.20 31 41 CPD 2.92 No no 86 118/80 19 86 118/80 19 84 120/82 17 9.2 30 No N no
112 Kartiga 26 13630 G2P1L1 153 54 84 118/76 17 10.00 30 42 F.D 2.75 No no 84 120/80 17 83 120/80 18 80 118/78 17 9 29 No no no
113 Praveena 21 13634 Primi 152 50 81 120/76 18 9.60 28 42 F.D 2.78 No no 86 120/82 17 84 120/82 18 81 120/82 16 8.6 27 No no no
114 PRiya 25 13677 Primi 155 52 82 120/78 19 9.60 28 42 CPD 2.85 No no 86 120/84 18 83 120/84 19 78 120/84 17 8.6 27 No V no
115 Veerammal 22 13566 Primi 156 53 83 120/74 17 9.89 29 42 F.D 2.95 No no 84 120/82 18 85 120/82 18 84 120/82 19 8.89 28 No no no
116 Ganga bhavani 26 13676 Primi 149 50 84 118/78 18 9.60 28 41 F.I 2.85 No no 85 120/82 19 81 120/82 17 80 118/78 19 8.6 27 No no no
117 Vijayakumari 22 14087 G2P1L1 150 51 82 130/76 17 9.80 28 41 PFtoP 2.75 No no 86 118/80 19 84 118/80 18 78 120/86 18 8.8 27 No no no
118 Sujatha 19 14155 Primi 151 53 82 130/86 18 10.00 30 42 S.O 2.75 No no 86 120/82 20 83 120/82 19 81 118/80 19 9 29 No N no
119 Kavitha 28 14171 Primi 152 52 81 128/78 19 10.00 30 41 F.D 2.85 No no 85 118/82 19 83 118/82 19 84 120/80 18 9 29 No no no
120 Jaishree 23 14116 Primi 151 50 83 118/80 17 9.60 28 42 CPD 2.90 No no 84 116/78 17 81 116/76 18 83 118/76 19 8.36 27 No no no
121 Anandhi 29 14187 Primi 153 52 81 120/80 18 9.80 29 42 Breech 2.88 No no 84 120/80 17 84 120/80 17 80 120/78 19 8.8 28 No no no
122 Vasanthi 25 14158 Primi 153 51 84 118/80 18 9.80 29 41 F.D 2.92 No no 84 118/82 18 86 118/82 18 81 118/78 20 8.8 28 No no no
123 Suganya 22 14423 Primi 150 54 86 118/76 17 9.60 28 42 F.D 2.85 No no 85 120/80 18 85 120/80 19 84 120/76 17 8.6 27 No no no
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124 Shakthi 26 14138 G2P1L1 155 53 81 118/80 18 9.80 29 41 CPD 2.83 No no 86 120/82 19 84 120/82 19 83 126/78 18 8.8 28 No N no
125 Sandhiya 21 14288 Primi 152 50 82 124/80 17 9.80 29 42 F.D 2.78 No no 85 124/82 20 85 124/82 19 84 120/78 19 8.8 28 No no yes
126 Subalakshmi 27 14263 Primi 151 51 81 118/86 17 9.60 28 42 F.I 2.80 No nn 86 120/84 19 85 120/84 19 81 118/82 19 8.6 27 No no no
127 Poongodi 20 14243 Primi 151 50 82 120/80 19 9.80 29 41 F.I 2.80 No no 85 122/82 19 81 122/82 19 84 120/76 19 8.8 28 No N no
128 Nishanthi 25 14190 G2P1L1 155 53 83 120/78 19 9.69 28 42 F.D 2.95 No no 86 120/80 19 85 120/80 19 82 120/80 19 8.6 27 No no no
129 Yamuna 21 14251 Primi 150 51 81 120/78 18 10.20 31 41 CPD 2.90 No no 86 124/84 18 86 124/84 18 78 129/86 18 9.2 30 No no no
130 Naveena 26 14227 Primi 154 52 84 120/80 19 9.60 28 42 F.D 2.92 No no 85 120/80 19 80 120/80 19 81 120/84 17 8.6 27 No no yes
131 Lakshmi 22 14363 Primi 151 53 85 118/80 19 9.00 27 39 CPD 2.85 No no 85 116/78 19 83 124/84 19 79 121/84 19 8.6 26 No D no
132 Sonia 25 14504 Primi 152 54 81 120/78 17 10.00 30 42 F.D 2.78 No no 87 120/76 20 84 120/80 18 83 120/80 19 8.2 29 No no no
133 Latha 20 14484 Primi 150 52 82 120/80 18 9.60 28 41 F.D 2.82 No no 86 118/82 19 85 120/82 19 81 121/78 18 8.8 27 No no no
134 Seetha 26 14417 G2P1L 156 53 83 118/80 18 9.80 29 42 F.D 2.88 No no 86 120/80 17 84 120/82 20 79 120/80 19 8.6 27 No no no
135 Mahalakshmi 22 14479 Primi 154 53 84 118/78 19 9.80 29 41 Breech 2.87 No no 85 118/80 18 83 120/86 21 81 118/86 17 8.8 28 No no no
136 Subitha 28 16482 Primi 151 50 82 120/78 18 9.80 29 42 F.I 2.88 No no 84 120/84 19 83 120/78 19 83 120/80 18 8.8 28 No N no
137 Arokiamary 23 16492 Primi 153 52 83 118/78 17 9.60 28 41 CPD 2.83 No no 85 118/84 19 85 118/80 19 82 120/82 19 8.8 28 No no no
138 Dhivya 27 14550 G2P1L1 151 50 84 130/86 17 9.80 29 42 F.D 2.89 No no 85 120/80 18 84 116/82 19 81 120/80 17 8.6 27 No no no
139 Savithri 24 14581 Primi 154 52 82 110/78 18 9.60 28 43 PFtoP 3.00 No no 85 118/86 17 83 120/80 19 83 120/80 17 8.6 28 No no no
140 Monisha 22 14594 Primi 155 51 82 118/78 18 9.80 29 42 F.D 2.70 No no 87 120/84 18 84 120/80 20 80 118/80 18 8.8 27 No no no
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141 Kasthuri 21 14616 Primi 149 50 83 120/80 19 9.80 29 40 S.O 2.65 Y yes 85 120/78 19 84 120/82 20 79 118/86 19 8.8 28 No no no
142 Megala 26 14200 G2P1L1 156 54 81 118/80 17 9.60 28 42 CPD 3.70 No no 85 118/80 19 85 118/80 19 83 120/80 19 8.6 27 No N no
143 Ganhimathy 21 14599 Primi 152 51 82 120/76 17 9.80 28 41 F.D 3.15 No no 85 120/76 18 83 118/80 18 84 120/80 17 8.8 27 No no no
144 Sumathy 25 14689 Primi 151 50 83 118/80 18 10.20 31 42 S.O 2.40 No no 85 118/76 19 84 120/76 18 82 118/80 18 9 30 No no no
145 Srividhya 20 14695 Primi 155 52 82 120/80 17 10.00 30 41 Breech 2.65 No no 86 120/78 18 86 120/80 19 81 120/80 19 9 29 No V no
146 Vanitha 23 14731 Primi 153 51 83 116/78 19 10.20 31 43 F.I 3.20 No no 86 120/76 18 83 120/80 17 82 118/81 19 9.2 30 No no no
147 Hemavathy 21 14743 Primi 154 52 84 118/70 18 9.80 29 44 CPD 2.75 No no 84 120/86 19 81 118/80 17 84 120/80 19 8.8 27 No no no
148 Meena 23 14629 Primi 151 54 81 118/70 17 9.60 28 45 PFtoP 2.83 No no 84 118/80 17 86 120/80 17 81 120/80 19 8.6 27 No no no
149 Megala 24 14533 G2P1L0 153 52 82 118/86 19 9.60 28 40 F.D 2.80 No no 86 120/80 17 84 120/80 18 82 118/80 18 8.6 27 No N no
150 Kavitha 21 14691 Primi 150 51 81 120/80 18 9.60 28 42 F.I 2.90 No no 85 117/82 19 80 120/82 18 83 118/82 19 8.6 27 No no no
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1 Bhagialakshmi 25 1835 Primi 152 53 82 120/80 19 9.60 28 42 CPD 2.84 439 No no 86 120/77 18 84 120/78 19 82 120/78 19 8.1 26 no no no
2 Pramila 30 1021 G2P1L1 152 53 80 118/78 19 9.80 29 41 CPD 2.85 436 No no 85 118/76 19 84 118/86 19 80 118/76 18 8.3 27 no no no
3 Pushpa 20 158 Primi 151 53 81 116/78 17 10.00 30 41 F.D 2.80 439 No no 84 114/77 19 85 122/77 18 80 116/78 19 8.5 28 no no no
4 Durga 26 431 Primi 152 53 82 122/78 18 9.60 28 43 S.O 2.75 440 No no 87 120/78 18 85 128/76 17 83 118/86 17 8.1 26 no N no
5 Jaya 18 545 Primi 153 51 82 120/80 19 9.60 28 45 F.D 2.82 442 No no 86 120/76 18 80 118/86 19 82 120/78 19 8.1 26 no no no
6 Vimala 21 85 G2P1L1 152 53 81 110/80 18 9.80 29 42 FI 2.80 439 No no 87 118/77 19 84 122/76 17 81 118/86 18 8.3 27 no no no
7 Reshma 27 140 Primi 153 51 82 130/78 19 10.00 30 44 F.D 2.78 495 No no 86 118/76 18 85 120/82 19 82 128/78 18 8.5 28 no no no
8 Elavarasi 20 283 G2P1L1 152 52 80 110/80 19 10.20 31 44 PFtP 2.89 960 Y yes 80 120/74 19 84 116/76 18 80 120/82 19 8.0 24 yes V no
9 Rajeshwari 22 512 Primi 153 50 81 120/80 18 9.60 28 42 CPD 3.00 436 No no 87 120/72 19 84 118/78 19 80 118/76 19 8.5 26 no no no
10 Suganya 25 163 Primi 151 53 82 118/78 17 9.80 29 41 F.D 2.65 436 No no 84 118/76 18 85 116/76 20 81 126/78 20 8.3 27 no no no
11 Manjula 23 95 Primi 152 53 81 121/78 18 10.00 28 42 Breech 2.78 439 No no 86 124/84 18 84 120/82 19 82 118/78 16 8.0 26 no no no
12 Samabanu 22 45 G2P1L1 151 50 82 118/78 19 9.80 29 41 CPD 2.85 438 No no 87 120/76 19 85 120/76 19 80 116/84 19 8.4 27 no N no
13 Alia 31 212 Primi 152 52 82 120/80 18 9.60 28 43 F.D 2.78 440 No no 85 120/70 19 84 120/82 19 82 120/86 19 8.0 26 no no no
14 Yamini 25 376 Primi 153 53 82 118/78 19 9.80 29 44 PFtP 2.83 570 Y yes 86 118/74 19 84 110/76 18 82 118/78 18 8.2 27 no no no
15 Shalini 24 345 Primi 153 53 85 120/72 18 9.80 29 41 CPD 2.82 440 No no 84 118/76 19 85 120/76 17 82 118/78 17 8.1 27 no no no
16 Chellathai 20 414 Primi 151 52 81 118/76 19 9.60 28 38 CPD 2.85 439 No no 86 120/74 18 84 116/77 19 80 118/86 15 8.1 26 no no no
17 Mahadevi 21 421 G2P1L1 152 50 78 120/80 18 9.80 29 42 S.O 2.78 438 No no 86 118/78 19 85 128/76 17 83 120/78 19 8.2 27 no no no
18 Manjula 22 462 Primi 153 52 81 118/76 19 9.60 28 42 F.D 2.85 600 Y yes 86 120/70 18 86 118/76 17 82 140/78 20 8.0 25 no no no
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19 Devipriya 19 508 Primi 152 53 80 120/76 18 9.80 29 43 CPD 2.82 441 No no 87 118/76 18 84 120/84 18 82 120/82 19 8.1 27 no no no
20 Ramya 26 501 Primi 153 52 81 122/72 18 9.60 28 42 F.I 2.87 443 No no 84 120/77 19 80 118/79 19 83 128/78 19 8.1 26 no no no
21 Therasa 22 550 Primi 154 51 82 120/80 19 9.60 28 45 F.D 2.85 438 No no 89 118/76 19 82 120/82 19 84 120/78 18 8.1 27 nn N yes
22 Rani 22 599 G2A1 151 53 83 120/80 17 10.20 31 41 CPD 2.87 443 No no 86 120/74 19 85 118/80 19 81 120/79 18 8.7 29 no no no
23 Chandrakala 25 604 Primi 150 53 83 118/78 18 10.00 30 42 CPD 2.88 605 Y yes 84 110/80 19 83 116/77 19 82 124/86 17 8.5 29 no V no
24 Usha 25 666 G2P1L1 151 53 83 120/82 18 10.20 31 42 CPD 2.84 560 Y No 84 120/76 18 85 120/86 19 82 128/78 19 8.7 27 no no no
25 Samabanu 18 730 Primi 152 52 82 118/78 18 9.80 29 44 F.I 2.78 442 No no 86 118/78 18 85 118/84 19 81 124/79 18 8.3 27 no no no
26 Deepika 21 803 Primi 153 50 84 120/86 19 9.60 28 42 F.D 2.80 441 No no 84 120/76 19 84 120/78 19 82 122/86 19 8.1 26 no no no
27 Rihana 28 943 Primi 152 51 83 118/78 17 9.80 29 43 F.D 2.84 436 No no 86 118/76 19 85 118/847 18 82 118/78 19 8.3 27 no no no
28 Surya 20 978 G2A1 153 53 84 120/82 19 9.60 28 41 CPD 2.78 432 No no 84 120/74 18 84 120/77 17 83 120/84 18 8.1 26 no no no
29 Sumathi 22 947 Primi 154 53 85 130/78 18 9.80 29 42 F.D 2.78 435 No no 86 120/76 19 85 118/77 17 83 122/80 19 8.3 27 no no no
30 Mary Jesintha 26 771 Primi 151 50 80 120/80 17 9.60 28 40 S.O 2.60 440 No no 84 118/76 19 83 118/84 18 82 119/70 19 8.1 26 no no no
31 Lakshmi 23 1043 G2P1L1 153 53 78 126/86 18 9.80 29 40 Breech 3.05 940 Y yes 86 120/76 18 85 120/82 19 82 120/80 19 7.9 24 yes no no
32 Muthulakshmi 24 1014 G2P1L1 152 52 88 118/78 17 10.00 30 45 PFtP 2.75 440 No no 84 118/78 17 82 118/78 19 82 120/78 17 8.6 26 no no no
33 Hemalatha 27 1093 Primi 154 53 76 120/80 18 10.20 31 42 S.O 2.50 439 No no 86 116/76 18 85 120/72 18 81 122/78 18 8.7 29 no no no
34 Chandini 20 849 Primi 153 51 82 120/76 19 9.60 28 42 PFtP 3.20 441 No no 84 120/80 19 84 118/86 19 80 120/74 19 8.1 26 no N no
35 Kalaivani 30 1200 Primi 154 50 83 120/76 19 9.60 28 40 F.D 2.75 436 No no 86 121/80 18 85 118/82 18 80 118/70 19 8.1 26 no no no
36 Asha 22 1358 Primi 153 50 82 126/72 18 9.80 29 41 CPD 2.90 435 No no 84 122/76 19 84 116/76 20 86 116/82 18 8.3 26 no no no
37 Tamilselvi 25 1366 G2A1 154 52 81 1187/78 17 9.60 28 41 CPD 2.82 438 No no 86 124/80 19 85 120/82 17 78 118/78 19 8.0 27 no no no
38 Thenmozhi 21 1395 Primi 153 50 84 120/72 17 9.80 29 42 CPD 2.95 580 Y no 84 118/76 18 85 116/86 18 78 120/82 18 8.3 27 no V no
39 Prasanna 29 1391 Primi 153 50 81 118/76 18 9.60 28 42 F.D 2.85 442 No no 86 120/80 17 84 120/70 19 81 122/86 18 8.1 26 no no no
40 Mahalakshmi `20 1479 Primi 153 53 76 120/84 19 9.80 29 42 F.I 2.80 437 No no 84 120/80 17 84 118/84 19 80 124/78 19 8.3 27 no no no
41 Hema lakhmi 19 1493 G2A1 152 53 85 110/82 17 9.60 28 41 F.D 2.75 438 No no 84 120/80 18 85 117/78 18 80 118/80 18 8.1 26 no no no
42 Sunitha 21 1160 Primi 153 52 83 110/80 18 9.80 28 42 CPD 2.85 436 No no 86 118/76 19 85 116/76 18 81 122/86 19 8.0 26 no no no
43 Kalaiarasi 26 1650 Primi 152 53 82 110/76 18 9.60 28 41 F.D 2.84 632 Y no 84 118/78 19 84 120/76 17 82 120/80 19 8.1 26 no no no
44 Sumathi 22 1783 Primi 153 52 83 120/76 17 9.80 29 41 CPD 2.95 660 Y yes 85 120/76 18 84 118/78 18 82 118/78 18 8.1 27 no N no
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45 Selvi 32 180 G2P1Lo 153 53 82 120/70 18 9.60 28 42 S.O 2.65 439 No no 86 118/76 18 85 120/78 19 80 121/82 19 8.2 26 no no no
46 Padma 26 1900 G2P1L1 153 53 82 120/76 18 9.60 28 42 F.D 2.85 440 No no 86 120/78 19 85 120/84 19 80 120/80 19 8.1 26 no no no
47 Sarawathy 19 2052 Primi 152 52 81 120/80 19 9.80 29 41 CPD 3.20 438 No no 84 120/86 18 83 118/77 19 82 119/78 19 8.3 27 no no no
48 Chitra 20 2076 Primi 152 53 82 110/80 19 9.60 28 44 CPD 3.10 640 Y yes 85 120/77 19 84 119/76 18 83 118/78 18 8.1 26 no V no
49 Anjali 28 2780 Primi 153 50 83 120/82 18 9.80 29 42 CPD 3.25 439 No no 86 118/70 19 85 120/84 19 82 126/86 19 8.3 27 no no no
50 Bharani 21 2124 G2P1L1 152 50 84 118/72 19 9.60 28 41 F.D 2.92 442 No no 84 118/76 18 84 118/86 17 81 120/80 17 8.1 26 no no no
51 Ilakia 29 2295 Primi 153 50 82 120/76 19 9.80 29 42 CPD 2.98 435 No no 86 120/76 18 85 120/84 18 81 110/82 19 8.3 27 no no no
52 Eshwari 22 2344 Primi 152 50 83 118/76 17 10.00 30 38 PFtP 3.45 443 No no 84 118/74 17 83 118/84 19 80 120/78 18 8.5 28 no no no
53 Thamina 25 2261 Primi 151 53 82 120/78 18 10.20 31 42 F.D 2.85 439 No no 84 120/74 18 82 120/84 18 82 118/78 19 8.7 29 no no no
54 Sonu 30 2369 Primi 155 50 83 120/86 19 9.80 29 42 S.O 2.45 560 Y no 86 120/76 19 83 118/84 18 83 120/70 17 8.1 27 no no no
55 Saranya 23 2504 G2P1L1 150 53 82 118/78 19 9.60 28 41 F.D 2.85 436 No no 84 120/76 19 84 128/78 17 82 118/82 17 8.1 26 no N no
56 Thendral 25 2155 Primi 152 52 83 120/80 18 9.80 29 41 F.I 2.75 488 No no 86 118/76 19 85 118/78 17 84 120/82 16 8.0 27 no no no
57 Sarala 22 2502 Primi 153 50 81 120/82 17 9.60 28 41 Breech 2.65 433 No no 86 120/74 18 83 120/80 19 82 118/78 16 8.2 26 no no no
58 Chitra 21 2151 Primi 160 50 78 118/86 18 9.80 29 42 F.D 2.95 436 No no 86 118/76 19 84 122/84 18 82 128/80 17 8.0 27 no no no
59 Ranjitham 20 2516 Primi 149 52 85 120/86 19 10.00 30 42 F.D 2.85 432 No no 84 120/76 18 83 122/86 18 82 120/86 17 8.4 28 no no no
60 Meenatchi 21 2618 G2P1L0 152 53 82 118/76 20 10.20 31 41 CPD 2.90 870 Y yes 84 120/74 19 84 120/84 19 81 124/86 18 8.0 24 yes V no
61 Sundari 20 2310 Primi 153 51 83 120/76 19 10.00 30 41 F.I 2.75 450 No no 84 118/76 19 84 126/86 19 82 124/82 19 8.5 28 no no no
62 Pallavi 23 2717 Primi 154 53 84 120/82 18 9.80 29 42 F.D 2.90 436 No no 86 120/74 18 85 116/84 17 82 120/86 17 8.1 27 no no no
63 Jayashree 22 2416 Primi 153 52 81 118/76 17 9.60 28 42 CPD 2.83 440 No no 85 120/74 18 85 118/84 18 82 118/78 19 8.3 26 no no no
64 Tharani selvi 25 2326 G2P1L1 152 53 80 120/76 17 9.80 29 42 F.D 2.75 441 No no 86 118/76 19 84 116/78 18 83 122/86 17 8.1 27 no no no
65 Shobana 24 2832 Primi 153 53 78 120/78 18 9.60 28 43 S.O 2.68 438 No no 84 120/70 19 84 120/84 19 82 128/78 19 8.1 26 no no no
66 Lavanya 29 2895 Primi 153 51 88 118/78 19 9.80 29 40 CPD 2.95 520 Y no 86 120/72 18 85 120/84 19 80 120/80 19 8.0 27 no no no
67 Hemavathy 21 2880 G2P1L1 153 53 78 120/80 19 9.60 28 41 F.I 2.85 434 No no 86 118/76 19 84 118/84 19 82 120/78 19 8.1 26 no V no
68 Victoria 22 2810 G2A1 153 53 88 120/82 19 9.60 28 42 F.I 2.95 432 No no 86 120/76 19 84 124/78 19 82 128/86 19 8.0 26 no no no
69 Nandhini 18 3038 Primi 152 52 86 120/78 17 9.80 29 42 F.D 2.55 432 No no 85 120/76 19 85 125/76 19 81 124/78 18 8.3 27 no N no
70 Tamil elakkia 25 2762 Primi 153 53 80 110/80 18 9.60 28 45 S.O 2.65 700 Y yes 84 118/76 18 84 118/84 18 80 119/74 19 8.1 24 yes N no
328
328
440
330
331
327
328
326
328
330
520
328
410
330
329
328
326
326
380
340
328
320
685
560
329
326
112
111
110
110
112
110
108
110
185
112
110
106
108
110
120
111
112
105
114
113
120
108
106
105
140
104
71 Reeta 21 3115 G2P1L1 151 52 78 120/86 18 9.80 29 41 CPD 2.95 448 No no 86 120/80 18 84 120/78 18 81 120/84 19 8.3 27 no no no
72 Rasool Mariam 27 12719 Primi 154 53 82 120/82 19 9.80 29 44 PFtP 3.23 443 No no 84 118/78 19 84 120/80 19 82 118/78 18 8.3 27 no no no
73 Saranya 20 12124 Primi 153 53 83 110/80 19 10.20 31 43 PFtP 2.95 440 No No 86 114/76 17 85 124/84 19 82 110/82 19 8.7 29 no no no
74 Valli 22 12725 Primi 152 52 82 130/80 19 10.00 30 41 F.D 2.90 440 No No 84 118/80 19 84 120/76 20 82 120/80 18 8.5 28 no no no
75 Sasikala 31 12626 G2P1L0 152 53 84 118/78 17 9.60 28 41 Breech 3.10 540 Y no 86 110/70 18 85 120/78 18 83 122/78 19 8.5 26 no no no
76 Sangeetha 26 12744 Primi 153 53 81 118/78 18 9.80 29 42 CPD 2.95 442 No no 84 116/76 18 84 118/84 19 80 120/741 18 8.1 27 no no no
77 Surya 24 12759 Primi 151 53 83 120/80 19 9.60 28 42 F.D 2.75 442 No no 86 130/76 19 84 120/78 18 81 122/78 19 8.3 26 no N no
78 Amala 23 12635 G2P1L1 152 52 82 120/72 18 9.80 29 41 F.I 3.10 438 No no 85 120/76 19 85 118/80 18 80 121/70 19 8.1 27 no no no
79 Jayalakshmi 25 12770 Primi 153 53 84 118/78 19 10.20 31 43 CPD 2.85 438 No no 86 116/80 19 85 120/80 18 82 120/74 18 8.3 29 no no no
80 Gomathi 22 12822 Primi 152 53 82 110/78 18 10.00 30 42 S.O 2.65 429 No no 84 110/76 17 82 110/76 19 80 124/787 19 8.7 28 no no no
81 Asina 20 12788 Primi 153 52 82 120/76 19 9.60 28 45 F.D 2.75 970 Y yes 86 118/80 18 84 118/84 19 82 120/74 19 7.7 24 yes V no
82 Ram Shanhari 18 12330 Primi 152 53 83 118/78 19 9.80 29 42 CPD 2.95 436 No no 84 118/76 18 85 120/80 19 82 140/82 18 8.4 27 no no no
83 Amala 26 12553 Primi 153 51 82 120/80 18 9.60 28 41 F.D 2.85 438 No no 86 120/72 19 84 126/78 18 83 122/78 19 8.1 26 no no no
84 Anaddhi 21 12780 Primi 154 53 83 120/82 18 9.80 29 44 F.I 2.95 441 No no 84 118/76 19 84 124/86 19 80 120/82 19 8.3 27 no no no
85 Bharathi 22 12812 Primi 150 50 82 118/78 19 9.60 28 42 CPD 2.85 439 No no 86 120/74 19 85 124/78 17 83 118/84 18 8.1 26 no no no
86 Ushanandhini 28 12808 G2P1L1 151 51 82 120/80 19 9.80 29 42 Breech 2.90 535 Y no 86 118/76 17 83 120/78 17 82 110/82 19 8.3 27 no no no
87 Tulasi 25 12893 Primi 152 52 83 120/70 18 9.60 28 41 CPD 2.85 442 No no 84 120/80 18 82 118/84 18 83 124/78 17 8.1 26 no N no
88 Kavitha 25 12910 G2P1L1 153 53 82 120/76 18 9.80 28 41 FI 2.95 800 Y yes 88 120/76 19 84 128/76 18 82 118/78 19 8.0 24 yes V no
89 Devi Kala 22 12998 Primi 153 52 83 118/72 19 9.80 29 42 FD 2.95 438 No no 86 118/70 18 84 118/77 19 80 120/82 18 8.5 27 no no no
90 Dhanalakshmi 28 12811 Primi 153 53 82 120/70 19 9.60 28 45 F.D 2.85 438 No no 86 118/70 18 84 118/77 19 80 120/84 18 8.3 27 no no no
91 Sangeetha 21 12989 Primi 152 53 80 120/80 18 9.80 29 42 F.D 2.75 443 No no 87 120/70 19 85 118/78 17 84 118/78 19 8.1 26 no no no
92 Susmitha 26 12681 G2P1L1 153 51 81 118/76 19 9.80 29 43 CPD 2.80 440 No no 85 118/76 19 84 128/76 20 80 120/84 17 8.0 27 no no no
93 Dharani 20 12982 Primi 152 53 82 120/78 18 9.60 28 41 S.O 2.95 440 No no 86 120/74 19 80 118/80 19 84 118/80 17 8.1 27 no N no
94 Nanadhini 27 13047 Primi 151 50 84 118/78 19 9.80 29 44 CPD 2.78 439 No no 86 118/76 18 84 120/78 19 84 120/74 19 8.1 26 no no no
95 Devaki 23 13058 Primi 154 52 78 120/82 19 9.60 28 42 F.D 2.83 439 No no 88 120/70 17 85 118/78 19 83 126/80 19 8.2 26 no no no
96 Barkavi 29 13063 Primi 153 53 82 120/80 19 9.60 28 43 F.D 2.65 436 No no 88 110/86 17 84 120/86 19 83 120/84 19 8.1 26 no no no
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97 Gomathy 21 13091 Primi 150 50 80 120/98 18 9.80 29 42 PFtP 2.70 436 No no 87 120/74 19 85 118/76 18 83 120/82 19 8.3 27 no no no
98 Vanaja 22 13110 Primi 151 51 82 118/76 17 9.60 28 44 F.D 2.85 438 No no 88 118/76 18 84 120/86 19 80 120/80 19 8.3 26 no no no
99 Jaya 23 13024 Primi 152 50 83 120/82 18 10.20 31 40 F.D 2.80 436 No no 86 120/74 19 83 118/84 19 80 122/84 19 8.7 28 no no no
100 Menaka 20 12686 Primi 154 53 82 118/76 19 10.00 30 41 F.D 2.75 680 Y yes 85 118/76 17 84 120/84 19 82 118/80 19 8.5 28 no V no
101 Suguna 21 13461 G2P1L1 155 50 82 120/86 18 9.80 29 42 CPD 2.82 550 Y no 88 118/78 18 82 118/80 19 83 140/82 19 8.2 26 no N no
102 Ramya rani 30 13458 Primi 151 53 83 120/82 18 9.60 28 42 F.I 2.98 436 No no 87 120/76 19 84 124/82 19 80 120/78 19 8.1 24 no no no
103 Ramya 29 13517 Primi 150 50 84 118/81 17 9.80 29 41 CPD 2.95 435 No no 85 118/74 19 85 118/86 17 80 124/82 17 8.2 26 no no no
104 Hasina 20 13509 Primi 152 51 80 118/78 19 9.60 28 42 CPD 2.75 436 No no 86 116/77 18 84 120/84 18 83 116/70 19 8.2 26 no no no
105 Manjula 22 13424 G2P1L1 153 52 81 120/76 19 9.80 29 41 PFtP 2.83 439 No no 80 120/70 19 84 120/77 19 80 120/82 17 8.1 27 no no no
106 Kumari 26 13523 Primi 152 53 82 120/80 18 9.60 28 42 F.D 2.80 442 No no 87 118/76 19 85 118/77 19 81 126/80 19 8.3 26 no no no
107 Anitha 23 13554 Primi 153 52 83 118/76 18 9.80 29 42 CPD 2.95 740 Y yes 84 120/76 18 84 120/78 18 85 124/78 19 7.8 24 yes V no
108 Gayathri 21 12408 Primi 153 50 84 120/72 19 9.60 28 42 F.D 2.90 442 No no 86 118/74 19 85 120/78 18 81 120/82 19 8.4 26 no no no
109 Kanmani 27 13576 G2P1L1 152 50 83 118/76 18 9.80 29 41 PFtP 3.10 439 No no 84 120/70 19 84 118/86 19 80 124/76 18 8.5 27 no no no
110 Hemavathy 20 13513 Primi 152 53 82 120/78 19 10.00 30 43 F.D 3.00 440 No no 86 118/76 18 83 120/78 19 81 120/82 19 8.7 28 no no no
111 Devi 22 13599 Primi 153 52 81 118/78 19 10.20 31 42 CPD 2.90 434 No no 85 120/74 19 84 118/78 19 81 119/80 19 8.1 29 no no no
112 Taslima 25 13615 primi 152 53 84 120/76 18 9.80 29 41 F.D 2.85 433 No no 86 118/76 19 80 110/77 16 83 120/82 17 8.2 27 no N no
113 Divya 19 13564 G2P1L0 151 52 83 118/78 19 9.60 28 40 F.I 2.75 438 No no 84 120/80 18 84 120/78 19 82 120/86 18 8.1 26 no no no
114 Kalavathy 21 13515 Primi 152 50 82 120/76 19 9.80 29 41 Breech 2.85 540 Y no 86 118/72 19 83 118/80 19 80 118/70 19 8.2 27 no N no
115 Suryakala 26 13624 G2P1L1 151 53 82 120/76 19 9.80 29 42 F.I 2.85 440 No no 86 120/76 19 84 120/77 19 80 120/86 19 8.1 25 no N no
116 Revathi 21 13909 Primi 152 52 83 120/80 19 9.60 28 42 F.D 2.98 436 No no 85 118/76 18 84 124/78 19 83 128/78 18 8.3 26 no no no
117 Vasanthi 25 14156 Primi 153 53 82 120/86 17 9.80 29 42 CPD 3.15 700 Y yes 80 116/76 19 85 118/77 17 81 116/86 19 8.3 24 no no no
118 Karpagam 20 14149 Primi 151 51 81 118/76 18 10.00 30 42 F.D 2.95 436 No no 87 118/78 18 84 120/84 18 83 120/74 19 8.5 28 no no no
119 Abi Fathima 32 14176 G2P1L1 154 53 85 120/80 19 10.20 31 45 PFtP 2.85 437 No no 86 116/70 17 85 118/77 17 81 118/78 18 8.7 29 no no no
120 Thilagam 29 14816 Primi 153 53 82 118/78 19 9.80 29 41 F.D 2.75 440 No no 84 118/76 18 84 126/76 18 83 116/84 19 8.3 27 no no no
121 Jothi akshmi 22 14195 Primi 152 52 83 120/82 18 9.60 28 42 S.O 2.85 570 Y yes 86 118/76 19 83 118/78 19 84 118/76 19 8.2 24 no no no
122 Janaki 19 14161 Primi 151 53 82 118/76 19 9.80 29 41 Breech 2.80 443 No no 87 120/80 19 85 122/84 19 80 120/72 18 8.1 27 no no no
440
328
326
560
329
326
330
330
420
326
327
565
330
329
328
328
330
560
329
330
328
326
440
331
329
330
106
108
110
111
113
180
112
110
108
106
108
110
120
110
108
110
108
106
135
110
112
120
108
112
130
110
123 Janaki 25 14223 G2P1L1 150 53 83 120/80 19 9.60 28 42 F.D 2.75 438 No no 84 118/76 18 84 118/80 20 84 118/78 19 8.1 26 no N no
124 Poongodi 21 14183 Primi 151 50 82 118/76 18 9.80 29 42 F.D 2.88 442 No no 87 120/74 19 84 120/84 16 83 140/82 19 8.1 27 no no no
125 Kushboo 26 14260 Primi 153 53 82 120/78 19 9.60 28 41 F.I 2.95 442 No no 87 118/76 19 84 124/78 17 84 122/80 18 8.3 26 no no no
126 Sundari 23 14211 Primi 154 53 81 118/72 19 10.00 30 43 CPD 3.25 436 No no 84 120/80 18 85 122/84 18 83 122/78 17 8.5 28 no no no
127 Ammu 24 14251 Primi 153 53 85 120/76 19 10.20 31 42 CPD 3.10 435 No no 87 114/78 19 85 118/86 19 82 120/86 18 8.1 29 no no no
128 Rohini 29 14280 G2P1L1 152 53 80 118/76 18 9.80 29 43 F.D 3.25 520 Y no 80 118/76 18 80 116/78 19 81 122/74 19 8.1 27 no no no
129 Gowri 22 14249 Primi 152 52 78 114/80 19 9.60 28 42 F.D 2.55 444 No no 78 120/72 19 85 124/86 20 82 124/78 19 8.2 26 no N no
130 Indhu 27 14335 Primi 153 53 83 116/80 19 9.80 29 42 Breech 2.75 432 No no 86 118/77 19 83 126/76 15 83 122/80 18 8.3 27 no no no
131 Shobana 21 14353 G2P1L1 152 51 82 120/76 18 10.20 31 41 F.D 2.85 441 No no 84 120/70 19 82 126/78 19 82 122/74 19 8.1 29 no no no
132 Kamala 20 14498 Primi 153 53 82 120/80 19 10.00 30 42 CPD 2.95 440 No no 84 118/76 18 84 128/80 19 80 120/84 19 8.5 28 no no no
133 Mangadevi 29 15505 Primi 154 50 83 130/80 18 9.80 29 41 F.I 2.90 439 No no 86 120/76 19 84 124/74 19 80 120/78 18 8.3 27 no V no
134 Suvitha 21 14481 G2P1L1 152 52 82 120/80 9 9.60 28 41 S.O 2.75 426 No no 86 120/74 19 83 118/86 17 83 122/82 18 8.1 26 no no no
135 Dharani 22 14473 Primi 151 53 83 121/80 19 9.60 28 39 CPD 2.85 900 Y yes 84 118/77 19 82 118/78 18 83 122/86 19 8.1 24 yes V no
136 Hasina 25 16479 G2P1L1 151 52 82 120/80 19 9.80 29 41 Breech 2.80 690 Y yes 86 120/74 19 84 120/78 19 84 120/80 19 8.5 27 no V no
137 Selvi 21 14582 Primi 154 50 83 118/78 18 9.60 28 42 CPD 2.85 440 No no 84 118/74 18 82 118/86 19 80 120/82 18 8.1 26 no no no
138 Lakshmi 20 16469 Primi 153 52 82 116/82 19 9.80 29 43 F.D 2.75 439 No no 87 116/76 17 84 118/78 18 83 121/86 19 8.3 27 no no no
139 Arun Latha 26 14594 Primi 152 51 80 120/80 19 9.60 28 42 S.O 2.65 438 No no 85 120/70 19 84 120/78 19 81 118/78 17 8.1 26 no no no
140 Lakshmi 34 14475 G2P1L1 151 53 84 120/82 18 9.80 29 39 CPD 3.00 436 No no 86 118/74 19 84 118/82 19 80 118/76 19 8.3 27 no no no
141 Bharani 22 14597 Primi 152 52 82 118/78 19 10.00 30 42 CPD 2.95 438 No no 84 120/72 18 84 120/86 19 83 128/74 19 8.1 28 no no no
142 Tamilselvi 27 14607 Primi 152 53 82 120/82 18 10.20 31 41 F.D 2.85 570 Y no 86 110/82 19 85 118/76 20 80 118/78 16 8.5 29 no no no
143 Govindammal 21 14566 Primi 153 52 83 118/76 19 9.80 29 41 F.D 2.75 436 No no 85 118/77 17 84 120/84 19 83 116/84 17 8.7 27 no no yes
144 Usha 20 14580 G2P1L1 152 50 82 114/78 19 9.60 28 44 F.D 2.85 439 No no 86 120/74 19 84 118/84 20 83 120/82 19 8.3 26 no no no
145 Uma 23 14686 Primi 153 52 80 120/82 19 9.80 29 43 Breech 2.83 438 No no 88 118/76 19 84 120/70 19 82 121/86 19 8.1 27 no no no
146 Muniammal 22 14723 Primi 152 52 78 118/78 19 10.00 30 41 F.D 2.85 434 No no 88 120/70 17 84 118/78 19 82 119/82 18 8.3 28 no no no
147 Nandhini 24 14740 Primi 151 53 84 120/80 18 10.20 31 42 F.D 2.75 438 No no 87 118/74 19 84 120/77 17 81 120/74 18 8.5 29 no no no
148 Sangeetha 26 14158 Primi 152 53 76 118/76 20 9.80 29 43 CPD 2.90 439 No no 88 118/77 17 82 180/82 18 83 119/76 19 8.7 27 no no no
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149 Padmavathi 20 14594 G2P1L1 153 52 86 120/72 20 9.60 28 41 F.D 2.85 438 No no 86 118/76 19 84 120/78 19 81 118/84 19 8.3 26 no no no
150 Prema 21 14742 Primi 152 50 80 112/78 19 9.80 29 42 Breech 3.01 1,020 Y yes 87 120/74 19 84 118/76 19 82 120/80 18 7.5 22 yes V no860
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KEY TO MASTER CHART
Ht : Height
Wt : Weight
PR : Pulse Rate
BP : Blood Presure
RR : Restiratory Rate
HB : Haemoglobin
PCV : Packed Cell Volume (Haematocrit)
LSCS : Lower Segment Caesarean Section
BL : Blood Loss
BW : Birth Weight
FI :  Failed Induction
SO : Severe Oligaohydramnios
CPD : Cephalo Pelvic Disproportion
FD : Foetal Distress
PF to P : PROM with Failure to Progress
N : Nausea
V : Vomiting
D :  Diarrhoea
Pla.Delry : Placental Delivery
